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ABSTRACT 
Increasing prevalence of bacteria that carries resistance towards conventional antibiotics has 
prompted the investigation into new compounds for bacterial intervention to ensure efficient 
infection control in the future. One group of potential lead structures for antibiotics is 
antimicrobial peptides (AMPs) due to their characteristics as naturally derived compounds with 
antimicrobial activity. In that perspective, this thesis seeks to characterize the mechanism of 
action of small library of in silico optimized peptides. Following determination of peptide 
activity against E.coli, S.aureus and P.aeruginosa, toxicity was assessed revealing meaningful 
therapeutic indexes for the far majority of the peptides. Investigation of the peptides effect on 
bacteria uncovered rapid inhibition with signs of bacterial lysis together with increased 
bacterial size. Both visual and quantitative assays clearly demonstrated bacterial membrane 
disruption after 10 minutes, although signs of reestablished membrane integrity at lower 
concentrations were observed after two hours. The membrane disrupting effect was verified by 
measuring the release of calcein from bacterial mimicking liposomes. This uncovered the most 
active peptides as inducers of immediate release, indicating the kinetics of membrane 
permeabilization as an important determinant of bacterial activity. No secondary structure of 
peptides in the presence of different liposomes was observed, implying that this feature is not 
essential for bacterial and cytotoxic activity within this library of peptides. In conjunction, these 
findings provide strong indications of membrane disruption as the primary mechanism of 
bacterial inhibition for the tested peptides.  
RESUMÉ 
En stadig stigende forekomst af bakterier med resistens overfor konventionelle antibiotika har 
medført en øget aktivitet i forskning, som har til hensigt at finde nye molekyler til bekæmpelse 
af bakterier for at sikre effektiv infektionskontrol i fremtiden. En af de grupper af stoffer som på 
grund af deres antimikrobielle aktivitet og naturlige oprindelse har potentialet til at være 
skabelon for fremtidig udvikling af nye antibiotika, er antimikrobielle peptider (AMP). Med 
udgangspunkt i dette forsøger dette speciale at karakterisere virkningsmekanismen for et lille 
bibliotek af computer optimerede peptider. Efter at have bestemt aktiviteten af peptiderne mod 
E.coli, S.aureus og P.aeruginosa blev toksiciteten adresseret, hvilket afslørede meningsfulde 
terapeutiske indekser for langt størstedelen af peptiderne. Bestemmelse af peptidernes effekt 
på bakterie vækst og morfologi afslørede en hurtigtvirkende hæmning af bakterier med tegn på 
lysering og forøget størrelse af bakterierne. Både visuelle og kvantitative eksperimenter viste 
tydelig permeabilitet af bakterie membranen efter 10 minutter, selvom der efter to timer var 
tegn på genvending af membran integritet ved lavere koncentrationer. Peptidernes forstyrrelse 
af membranen blev verificeret ved at måle frigivelsen af calcein fra bakterie mimikerende 
liposomer. Dette viste, at de mest aktive peptider førte til øjeblikkelig frigivelse og indikerede 
dermed, at kinetikken i forbindelse med membran gennemtrængning er en vigtig parameter for 
antibakteriel aktivitet. Endelig blev sekundær struktur bestemt ved tilstedeværelsen af 
forskellige liposomer, hvilket ikke viste nogen veldefineret sekundær struktur. Dette indikerer, 
at sekundær struktur ikke er essentiel for hverken antibakteriel aktivitet eller toksicitet 
indenfor dette bibliotek af peptider. Sammenfattende tyder disse resultater kraftigt på, at 
membran gennemtrængning er den primære mekanisme for hæmning af bakterier for de 
testede peptider.    
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MOTIVATION AND SCOPE OF THE THESIS 
For a long time, the treatment of most infections in western countries has been considered a 
rather uncomplicated matter due to the effectiveness of various antibiotics. Fortunately that still 
applies, although the treatment of some bacterial infections has become gradually more 
complicated in recent years because of the increase in bacterial resistance against conventional 
antibiotics. This is made obvious by the fact that infectious diseases are the third leading cause 
of death in developed countries, despite the abundant availability of antibiotics (Nathan, 2004). 
Furthermore, the emergence of resistant strains of bacteria is increasing at an alarming rate 
especially in hospital settings where the use of antibiotics and the consequent selective 
pressure, is relatively high (von Nussbaum et al., 2006). The emergence of resistant bacteria 
such as methicillin-resistant Staphylococcus aureus (MRSA) was in 2005 estimated to have 
caused 94.000 infections leading to 19.000 deaths (Klevens et al. 2007). Together with other 
multi drug resistant (MDR) such as Pseudomonas aeruginosa and extended-spectrum-beta-
lactamase (ESBL) producing Klebisella pneumonia and Escherichia coli, they pose an increasing 
threat to public health (Fischback & Walsh, 2009). These facts are by themselves worrying, but 
if you add the fact that there has only been introduced a very limited number of truly new 
antibacterial agents to the market since the 60’s [Fig. 1], and a rapid declining interest from 
medical companies into development of new antibiotics, you have a development that calls for 
concern (Nussbaum et al., 2006; Fischbach & Walsh, 2009). 
Figure 1: Timeline of the discovery of the most important antibiotic classes, illustrating the innovation gap, (Fischbach & 
Walsh, 2009). 
Naturally, pharmaceutical companies have profit as their main objective and it would appear 
that the general consensus is that it is simply not sufficiently profitable to invest in the 
discovery of antibacterial drugs (Kresse et al. 2007). This can, at least in part, be explained by 
substantial generic penetration in the market of antibiotics which plummets the value of the 
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original patents. Furthermore, the period for treatment with antibiotics is in most cases 
restricted to only a few weeks, which in comparison to conditions that has a more chronic 
nature such as depression or cancer, limits the potential of reimbursing the investment put into 
antibiotic drug development (Projan, 2003, Fischbach & Walsh, 2009). With a declining effort 
from pharmaceutical companies into antibacterial research together with the increasing 
prevalence of resistant bacteria, it calls for new strategies to combat infections. In that 
perspective, it is important to pursue the development of new antimicrobial agents, with a novel 
mode of action, to ensure that we will be able to cure life threatening infections in the future. 
One group of compounds with a different mode of action that has the potential to assist in the 
fight against infections is antimicrobial peptides (AMP).   
 
AMPs are a natural component of the innate immune system in a wide range of organism, acting 
as a first line of defense against various microbes.  AMPs have been isolated from a great 
number of organisms ranging from bacteria to plants, invertebrates and vertebrates, thereby 
demonstrating their prevalence in virtually all branches of life (Jenssen et al., 2006).  In relation 
to their abundance among different kinds of organisms, the biological effect varies from direct 
bacterial inhibition to immune modulating, proving their versatility as effector molecules 
(Jenssen et al., 2006). As natural compounds with an antimicrobial effect, AMPs have naturally 
drawn the attention of scientist to investigate their potential as future antimicrobial agents. This 
has led to the identification of more than 1000 AMPs (Wang et al. 2009), and numerous 
attempts to improve activity by modifying natural AMPs or the de novo design of AMPs 
including the use of unnatural amino acid analogues (Godballe et al. 2011). Although a large 
number of natural and synthetic antimicrobial peptides have been studied, there is still today, 
quite a bit yet to be unraveled about the exact nature of bacterial inhibition exerted by these 
peptides. Over the years, evidence suggesting that cationic antimicrobial have a wide range of 
effects against bacteria, ranging from unspecific membrane perforation to specific inhibition of 
intracellular targets has emerged (For review see Hale & Hancock, 2007). Although different 
targets have been identified, a detailed characterization of the mode of action has only been 
carried out on a minority of peptides. To truly take advantage of AMPs and make use of their 
potential as lead structures for bacterial intervention, it is therefore in that perspective that the 
scope of this thesis is to elucidate the mechanism of action of a set of different synthetic 
antimicrobial peptides. A thorough characterization of the antimicrobial activity would not only 
unravel the potential of the tested peptides but also contribute to a greater understanding of the 
general structure function relationship of other antimicrobial peptides as well. 
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To start of the investigation into characterization of the mechanism of action, different libraries 
of synthetic peptides were tested against bacterial reference strains to identify peptides with an 
antibacterial activity that could justify further studies. One library was based on Bactenecin 
(RLCRIVVIRVCR) isolated from bovine, one of the shortest peptides with broad spectrum 
activity isolated from nature (Spindler et al., 2011). A linear variant of Bactenecin was named 
Bac2a (RLARIVVIRVAR) and this peptide was chosen for further optimization studies, owing to 
its improved activity (Hilpert et al. 2006). After high throughput screening of numerous 
variants, a shortened peptide with improved activity against both gram positive and negative 
bacteria named Bac8c (RIWVIWRR), was identified (Hilpert et al. 2005). In an attempt to further 
improve the activity of Bac8c, various mutants were constructed to be used in this study. This 
was done by changing the position of Arg and synthesizing truncated versions to estimate if a 
smaller peptide could retain activity. The potency of the resulting 7 peptides named Bac1-7 is 
evaluated against Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus reference 
strains in this study. 
Another library of computer optimized peptides, constructed by Fjell and colleagues, was also 
examined. These peptides were the result of an in silico screening, starting with almost 100.000 
9-mer peptides that over the course of numerous in silico optimizations was scored as the most 
active ones (Fjell et al. 2011). The 10 most active peptides from this optimization were selected 
for investigation in this study. To verify the activity of the peptides, minimal inhibitory 
concentration (MIC) testing was carried out against Escherichia coli, Pseudomonas aeruginosa 
and Staphylococcus aureus reference strains. Based on these initial studies the three most active 
peptides were selected for further studies to elucidate the mechanism of bacterial inhibition.  
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INTRODUCTION 
The following section will seek to introduce the components of bacteria that are important for 
interaction with AMPs and give a brief introduction to a bacterial mediated pathological 
condition that AMPs have the potential to alleviate. As antibiotics and AMPs are thought to 
target some of the same bacterial components and to serve as foundation for comparison of the 
inhibitory actions with peptides, a brief outline of the mechanism of action for the antibiotics 
used in this study will be presented. Finally, the bacterial processes and structures that mediate 
resistance will be briefly addressed, together with an introduction to the structure and 
characteristics of AMPs. 
BACTERIAL MEMBRANE COMPONENTS 
Bacteria are remarkable organisms with an extreme ability to adapt to their environment 
proven by their existence in virtually all habitats from e.g. hot springs to the arctic region (Wiley 
et al 2008).  Years of selective evolution have provided them with the components needed for 
survival under harsh conditions, one of them being the bacterial cell wall. The mechanical 
strength provided by the bacterial cell wall is an essential feature for bacteria to survive in 
conditions that often offer steep changes in osmolarity and temperature. Consequently, the cell 
wall that surrounds almost all bacteria is fairly rigid, essentially consisting of an interconnected 
mesh of cross-linked sugar derivates and different amino acids that altogether make up the 
peptidoglycan layer comprising the cell wall. Given the nature of peptidoglycan as an open mesh 
like structure, it does not pose a significant permeability barrier for compounds, even for gram-
positive bacteria which have a rather extensive layer of peptidoglycan (Franklin & Snow, 2005). 
The chemical structure of peptidoglycan is essentially the same for both gram-positive and 
gram-negative bacteria but the layer is much thicker in gram-positive bacteria where it can 
extend up to 80 nm in comparison to around 5 nm in most gram-negative bacteria (Wiley et al., 
2008). In addition to the difference in the thickness of the peptidoglycan layer, gram-negative 
bacteria have an extra outer membrane which is separated from the cytoplasmic membrane by 
the periplasmic space and the thin layer of peptidoglycan. In comparison gram-positive bacteria 
only have one membrane. Other important differences between gram-positive and gram-
negative bacteria are outlined in [Fig. 2].   
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Gram-negative bacteria primarily have lipid A in the outer leaflet and phospholipids as the main 
lipid structure in the inner membrane, thereby having an asymmetrically distribution of lipids 
across the outer membrane [Fig. 2], (Kumar & Schweizer, 2005). This make the outer 
membrane of gram-negatives a highly efficient barrier, which is poorly diffusible for many 
compounds because of the dense packing 
of the lipid A, leaving the uptake of 
hydrophilic compounds largely to ion 
selective channels called porins (Kumar & 
Schweizer, 2005; Franklin & Snow, 2005). 
The cytoplasmic membrane of gram-
negative and gram-positive bacteria also 
acts as a barrier but allows for selective 
uptake of various components and 
enables the chemical 
compartmentalization that is necessary 
for metabolisms to occur.  The exact 
nature of the lipid composition that make 
up the bacterial cytoplasmic membrane varies substantially between bacterial species but a 
general feature that does apply, is that all bacteria have at least 15 % anionic lipids- typically 
either phosphatidylglycerol (PG) or cardiolipin (CL) or both [Fig. 3] (Epand & Epand. 2009). 
Figure 3: Major membrane constituents of bacteria. 
Phosphatidylglycerol (PG), Cardiolipin (Cl) and 
Phosphatidylethanolamine (PE). Adapted from Avanti lipids, 
examples are from E.coli.  
   
 
Figure 2: A: Outline of the gram-positive membrane and cell wall. Gram-positive bacteria only have one plasma 
membrane protected by a thick and extensive layer of cross-linked peptidoglycan which is penetrated by lipoteichoic 
and anchors the negatively charged teichoic acids which all together contributes to the rigidity of the cell wall. B: Gram-
negative bacteria have both an outer and inner membrane separated by the periplasmic space where the thin and less 
extensive peptidoglycan layer is located. Furthermore, the outer membrane holds porins and the negatively charged LPS 
protruding from the membrane. Adapted from Lolis & Bucula, 2003 
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Furthermore, zwitterionic lipids which usually is phosphatidylethanolamine (PE), contributes in 
varying degrees to the membrane composition of bacteria (Teixeira et al., 2012). Generally 
speaking, gram-negative-bacteria have a higher content of PE whereas some gram-positive are 
practically depleted of zwitterionic lipids [Table 1] (Epand & Epand, 2009). The electronegative 
nature of the bacterial membrane, induced by PG and CL, are thought to be the main contributor 
of selectivity exerted by AMPs towards bacteria because of charge mediated attraction to the 
positively charged AMPs (Matzuzaki, 2009).  
TABLE 1: Bacterial membrane lipids 
 
 
 
Another membrane component of bacteria which is of special interest, is the LPS of gram-
negative bacteria, both because it is believed to be the first interaction with AMPs owing to it 
position protruding from the outer membrane but also because of its characteristics as a 
pyrogen. LPS is one of the main components of the outer membrane of gram-negative bacteria 
providing both structural support, protection and in some cases aiding adhesion. Although LPS 
is rather heterogeneous, varying greatly between bacterial strains, the buildup of LPS reveals 
three distinct structural motifs defining the general structure [Fig 4].  
Figure 4: Schematic of the general features of LPS structure with Lipid A, core oligosaccharide and the O-antigen of 
varying length. The different colours represent different components, but the names are left out for simplicity. 
The lipid-A domain of LPS consist of lipids and as a natural consequence is also the structure 
that anchors LPS to the membrane (Franklin & Snow, 2005). The composition of Lipid-A with 
only saturated fatty acids, contributes to a membrane structure with low fluidity (Kumar & 
Scweizer, 2005). Lipid-A is furthermore the most conserved domain of LPS and accounts for 
      Phosphatidylglycerol        Phosphatidylethanolamine      Cardiolipin  
E.coli 17 80 3 
P.aeruginosa 21 60 11 
S.aureus 58  42 
Contribution of selected lipids in percentage to the cytoplasmic membrane of the bacteria used in this study. The 
numbers presented are mean values based on data from (Epand et al. 2007, Morein et al. 1996, Teixeira et al. 2012). 
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most of the toxic activity which can lead to septic shock – addressed in the next section. The 
core oligosaccharide is build from a short chain of sugars that serves to link the lipid-A and O-
antigen units and is a rather conserved entity within bacterial genera (Franklin & Snow, 2005). 
The O-antigen is a repetitive structure of oligosaccharides, consisting of various sugars 
composing the outermost part contributing to the overall negative charge of LPS (Schneck et al., 
2010). The exact length and nature of the sugars in the O-antigen, varies considerably between 
bacterial strains and species, thereby comprising the most heterogeneous part of LPS and 
explains why the molecular weight of different LPS, varies considerably between strains and 
species (Caroff et al., 2002). Furthermore, variation in the length of the O-antigen chain gives 
rise to different types of LPS. Full length chain is designated smooth whereas shortened or 
absent is labeled rough mutants [Fig. 4], originating from microscopy studies of the respective 
morphology of bacterial colonies (Caroff et al., 2002).  
Due to the negative charge induced, both by sugar components of the O-antigen and phosphates 
(Bononi et al., 2008), LPS is stabilized by divalent cations to counteract the electrostatic 
repulsion between the negatively charged entities (Kotra et al., 1999; Zasloff, 2002; Franklin & 
Snow, 2005). 
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SEPSIS 
On top of the substantial complications that bacterial infections can cause on their own, a 
pathological condition referred to as sepsis can arise in relation to infections. Various bacteria 
can account for the infections that lead to sepsis but S.aureus and E.coli are the main 
contributors although sepsis can also be caused by other microbes such as fungi and viruses 
(Annane et al., 2005). Sepsis is a condition in which the immune response towards a severe 
microbial infection results in inflammation throughout the body, recently defined as “a 
condition of infection with evidence of systemic inflammation” (Annane et al., 2005). To fulfill the 
criteria of sepsis, at least two of the following systemic inflammation conditions has to be 
present; change in body temperature, change in leukocyte count, tachycardia and rapid 
breathing (Annane et al., 2005). Severe sepsis is characterized by the addition of organ failure to 
the symptoms present in sepsis (Russel, 2006). Septic shock is the progression from severe 
sepsis, where patients present with hypotension that cannot be alleviated by treatment with 
fluids (Russel, 2006). Sepsis is commonly not life threatening but around 9% of patients with 
sepsis move on to develop severe sepsis, and 3% of patients with severe sepsis come to suffer 
from septic shock (Annane et al., 2005) which display an attributable mortality rate around 1 
out of 4 (Annane et al., 2003). In addition to the mortality, sepsis is a significant burden for the 
healthcare system, demonstrated by the fact that patients with sepsis occupied 45% of bed days 
in intensive therapy unit in a UK study (Kendrick & Jones, 2007). Furthermore, 750.000 cases of 
sepsis are estimated each year and these cases add up to a cost of $ 16,7 billion annually in the 
US (Angus et al., 2001). Evidently, sepsis is today a major concern and the frequency of patients 
that develop sepsis is expected to increase in the future as a result of an aging population, 
increase in the prevalence of resistant microbes and an increasing rate of high-risk surgery 
(Russel, 2006).   
Sepsis in patients arises from cells of the innate immune system recognizing various conserved 
microbial molecules including LPS, which sets of an inflammation cascade that can result in 
sepsis.  It has been shown that LPS by itself stimulate a response in dendritic cells very similar 
to the response set off by intact E.coli cells (Huang et al., 2001). Additionally, it has been shown 
in studies with rabbits that superantigenic toxins from gram positive bacteria induce a state of 
hypersensitivity towards LPS which can transform tiny amounts of LPS that were previously 
harmless, into inducers of toxic shock syndrome (Dinges & Schlievert, 2001). This could make 
way for a rationale to intervene with drugs that neutralize LPS, even in the event that the 
infection was primarily caused by gram-positive bacteria (Cohen, 2002). During a gram-
negative infection, bacteria will inevitably shed LPS together with other cell components owing 
to normal growth and cell division, thereby making these components available for recognition 
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by macrophages and neutrophils. LPS will not by itself, be recognized by immune cells but need 
to bind the liver produced Lipopolysaccharide binding protein (LBP) that circulates the body. 
The LPS-LBP complex will be recognized by the CD14 receptor which is primarily expressed on 
macrophages and lead to activating of the Toll like receptor 4 (TLR4) with assistance from the 
MD-2 protein (Cohen, 2002). This will in turn activate macrophages and stimulate the secretion 
of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α which will set off the inflammation 
cascade (Russel et al., 2006). This leads, among other things, to the recruitment of monocytes 
and neutrofiles, histamine release and activation of the coagulation cascade, all potentially 
leading to the various adverse effects of septic shock,  [Fig. 5], (Cohen, 2002). This response 
towards infection is a complex and well-orchestrated chain of events, with the purpose of 
initiating an appropriate response that is 
highly efficient in controlling infection. This 
includes the production and secretion of 
cytokines and other stimulatory molecules, 
which are absolutely essential mechanisms 
in activating a potent immune response. In 
the event that prolonged production of 
inflammatory mediators, results in 
uncontrolled activation of the immune 
system throughout the body, a state of 
severe sepsis could progress. 
Although there have been a steady progress 
in therapeutic options to control the 
development of septic shock over the years, most treatments has the management of symptoms 
as their target. Previous therapeutic strategies against sepsis has mostly focused on single 
elements of either the pathway leading to activation immune cells, antagonist against various 
cytokines or single symptoms related to sepsis, all with limited success (Lolis & Bucula, 2003). 
There is no easy way of treating sepsis as it is a multifaceted and complex pathological condition 
but AMPs has some of the features that could hold promise for a treatment that could target 
both the bacteria together with neutralizing LPS and modulate the immune response, thereby 
restraining the development of sepsis.    
Figure 5: Simplified outline of the pathogenesis of sepsis. 
Microbial components lead to activation of multiple cascades 
leading to sepsis and organ failure. Edited from (Cohen, 2002).   
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Figure 7: Common β-lactam structure with 
the β-lactam ring highlighted; R is H in 
Penicillin G and NH2 in Ampicillin. 
 
ANTIBIOTICS 
As our current treatment of bacterial infections is highly dependent on antibiotics and some 
antimicrobial peptides are believed to target the same bacterial components, a brief 
introduction of the antibiotics used in this study will 
be presented in the following section. As a natural 
consequence of that, the following section is in no 
way an exhaustive review of antibiotics but serves 
to provide the reader with necessary knowledge to 
fully benefit from the rest of the thesis.  
Drug discovery in general centers on the dogma of 
targeting only the processes needed for disease 
prevention without any adverse effects. Hence, to 
meet this general criterion the development of 
antibiotics relies on targeting processes or 
structures that are unique for bacteria such as the 
bacterial cell wall biosynthesis. Another strategy is 
to target elements in bacteria, such as protein 
synthesis and DNA replication/repair machinery 
that are sufficiently different in structure from their 
human counterparts to allow selective inhibition 
[Fig 6].   
 
CELL WALL INHIBITING ANTIBIOTICS 
While being, both an essential component for bacterial survival and bearing little resemblance 
to any structures in animal cells, the bacterial cell wall has been a target for many antibacterials. 
Cell wall acting antibiotics are not limited to 
penicillins, which ampicillin used in this study belong 
to, but other cell wall inhibiting antibiotics are not 
within the scope of this thesis and are therefore not 
addressed further.  
Ampicillin differs from other penicillin drugs by the 
addition of an amino group, which renders the drug 
more efficient against gram-negative bacteria due to 
Figure 6: Bacterial targets of the most common 
antibiotics. Adapted from Wright, 2010 
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increased permeability of the outer cell wall [Fig. 7], (Bryskier, 2005). Cell wall transpeptidases 
normally mediate the cross linking of the peptidoglycan strands in the peptidoglycan layer 
thereby providing the mechanical strength of the layer. The process of synthesizing the 
constituents of peptidoglycan layer takes place in the cytoplasma, whereas the cross-linking of 
strands occurs after transfer across the cytoplasmic membrane (Fisher et al., 2005). Penicillins 
acts by blocking transpeptidase enzymes, also known as penicillin binding proteins (PBP), in a 
competitive manner. The transpeptidase enzymes recognize the β-lactam ring of the β-lactams 
as a substrate (peptidoglycan D-alanyl-D-alanine) and thereby bind and opens the β-lactam 
structure. This intermediate structure is, as opposed to the normal D-alanyl-D-alanine, very 
slowly released, thereby effectively preventing new substrates from binding and in that way 
inhibiting cross-linking of the peptidoglycan layer. During normal cell growth, there is a 
continuous replacement and renewal of the peptidoglycan layer to accommodate growth and 
cell division. This process requires confined breakdown of the existing peptidoglycan to 
facilitate rearrangement and is mediated by peptidoglycan hydrolases and autolysins, both 
having amidase activity (Kohanski et al., 2010). The inhibition of cross linking in peptidoglycan, 
brought about by β-lactams, will thus result in a build-up of peptidoglycan precursor molecules. 
With the cell wall autolysins degrading the existing peptidoglycan layer, to enable 
rearrangement, with no cross-linking of precursors due to β-lactam inhibition, structural 
integrity is eventually lost which leads to osmotic cell lysis [Fig. 8] (Kohanski et al., 2010).  
 
 
 
  
  
 
Figure 8: Bactericidal effect of β-lactams due to inhibition of peptidoglycan cross-linking and the simultaneous activity of 
autolysins which adds up to the loss of peptidoglycan integrity resulting in bacterial lysis, (Kohanski et al., 2010). 
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POLYMYXINS  
Polymyxins are a group of antibiotics acting on the membrane of bacteria. The most interesting 
member of this group, in relation to this study, is Polymyxin B, although other compounds such 
as Polymyxin E (Colistin) and Polymyxin M also classifies as Polymyxins. Polymyxin B is a 
Bacillus polymyxa derived lipopeptide antibiotic (Zavascki et al., 2007), consisting of 
polycationic peptide ring attached to a lipid tail, [Fig. 9]. At physiological pH, the amino groups 
are protonated, giving a cationic 
charge of 5, which is believed to 
supply the electrostatic attraction 
towards the negative charged LPS, 
being the primary target. The 
interaction with LPS has inspired 
Polymyxin B to be investigated as 
an antibiotic for clinical use despite 
its systemic toxicity (Zavascki et al 
2007). The activity of Polymyxin B 
is believed to rely on electrostatic 
attraction with the negatively 
charged LPS, followed by the lipid tail interaction with the plasma membrane. Specifically, the 
cationic peptide ring displaces the stabilizing Ca2+ and Mg2+ cations from LPS in a competitive 
manner, because of the greater affinity of Polymyxin B towards LPS (Franklin & Snow, 2005). 
This leads to insertion of Polymyxin B into the outer membrane and subsequent membrane 
disruption, which facilitates additional uptake of Polymyxin B into the inner membrane 
(Zavascki et al 2007). Consequently, this result in membrane destabilization and subsequent 
leakage, eventually leading to cell death. Due to the mechanisms of action that relies heavily on 
interaction with LPS, Polymyxin B naturally only carries activity towards gram-negative 
bacteria. Because of its distinctive interaction with LPS it is believed to be the golden standard 
for LPS binding (Mares et al., 2009) which is also the purpose it serves in this study. 
  
Figure 9: Molecular structure of the polycationic peptide ring of 
Polymyxin B. 
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QUINOLONES 
Quinolones are a group of antibiotics that have the DNA replication machinery as their target, 
capable of inducing rather quick killing of susceptible bacteria (Drlica et al., 2008). 
Quinolones acts by shifting the equilibrium between cleavage and relegation of double strands 
of DNA, normally mediated by topoisomerase II. Quinolones acts by binding and trapping the 
topoisomerase-DNA complex in the transition between cleavage and relegation, which 
effectively prevents rejoining of the DNA strands and results in accumulation of DNA breaks. 
The double strand nicks in the bacterial DNA induced by quinolones, prevent the action of DNA 
polymerases leading to accumulation of DNA damage and halted DNA replication (Franklin & 
Snow, 2005), although this alone cannot account for the rapid and bactericidal effect of 
quinolones. Low concentrations of quinolones tend to act in bacteriostatic manner, believed to 
depend on inhibition of replication forks, whereas higher concentrations of quinolones is 
thought to mediate its lethal actions by inducing chromosome fragmentation (Drlica et al., 
2008). The accumulation of double stranded DNA breaks, together with inhibition of 
topoisomerases can induce the SOS response, which among other things prompts error prone 
DNA polymerases to be expressed in an attempt to circumvent the halted DNA repair. Though, 
induction of the SOS response is protein synthesis dependent, quinolones can induce cell death 
in a protein dependent and independent manner depending on the exact drug [Fig. 10] (Drlica 
et al., 2008). 
 
 
 
Figure 10: DNA damage induced by Quinolone leading to the bacteriocidal effect of Quinolones in either protein 
dependent or independent manner, (Kohanski et al. 2010). 
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Also, topoisomerase IV, responsible for decatenation of replicated daughter DNA-molecules, is 
affected by quinolones and topoisomerase IV is generally considered the primary target of 
inhibition in gram-positive bacteria (Kohanski et al.,, 2010). In case of topoismerase II being the 
primary target, DNA replication is inhibited in a matter of 
minutes whereas topoismerase IV targeted inhibition 
develops more slowly (Drlica et al., 2008). The quinolone 
drug of choice used in this study is ciprofloxacin [Fig. 11] 
because of its improved activity against gram positive 
bacteria (Franklin & Snow, 2005). Ciprofloxacin stand out 
from classic quinolones by the addition of a Fluorine atom, 
which is responsible for the increased activity against 
gram-positive bacteria.    
PROTEIN SYNTHESIS INHIBITORS 
The aminoglycoside antibiotics are considered broad spectrum antibiotics with activity against 
gram negatives and staphylococci plus gram positive bacilli (Bryskier, 2005). The reason for 
different efficiency and spectrum of activity, for the different members of this group of 
antibiotics should primarily be attributed to different penetration capabilities of the bacterial 
membranes (Bryskier, 2005). The remarkable effectiveness of tobramycin [Fig. 12], used in this 
study, against P. aeruginosa is as an example related to 
its improved penetration capabilities. Aminoglycosides 
as a group are characterized by containing various 
sugars with amino groups and are cationic at 
physiological pH. The positive charge of aminoglycosides 
serves to help the binding of the anionic 16s rRNA on the 
30s bacterial ribosomal complex (Franklin & Snow, 
2005). This has been shown to cause a conformation 
change in the complex between mRNA codon and aminoacyl tRNA which promotes tRNA 
mismatch and leads to mistranslated proteins (Kohanski et al., 2010). Dysfunctional proteins 
that are incorporated into the membrane disrupts membrane function, leads to metabolic 
disturbances and to production of hydroxyl radicals which all together contributes to the lethal 
effect on bacteria (Kohanski et al., 2010). Also, membrane leakage induced by incorporation of 
misfolded proteins into the membrane, facilitates increased drug uptake which results in 
complete ribosomal inhibition, further contributing to the inhibitory effect exerted by 
aminoglycosides [Fig. 13], (Bryskier, 2005). 
Figure 12: Molecular structure of Tobramycin. 
Figure 11: Molecular structure of 
Ciprofloxacin showing both the Quinolone 
scaffold and the addition of the Fluorine 
atom. 
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Figure 13: Bactericidal effect of aminoglycosides. Incorporation of misfolded proteins in the membrane disrupts 
membrane function leading to both increased uptake of aminoglycoside and production of hydroxyl radicals which 
contributes to the lethal effect against bacteria (Kohanski et al., 2010). 
Tetracycline [Fig. 14] is a bacteriostatic drug that originally was isolated from Streptomyces 
aureofaciens, binds the 30s bacterial ribosomal subunit and thereby prevents protein 
biosynthesis. More specifically, tetracycline prevents the 
rotation of the incoming aminoacyl-tRNA anticodon into 
the A-site, thereby preventing binding to the mRNA 
codon (Franklin & Snow, 2005). This results in 
premature release and no formation of peptide bonds. 
The binding of tetracycline is reversible, which also 
serves to explain the bacteriostatic nature of the drug 
(Bryskier, 2005). Although tetracycline is also able to bind 80s mammalian ribosome, selectivity 
towards bacteria is ensured by a higher affinity towards bacterial ribosomes and selective 
uptake and accumulation of the drug in susceptible bacteria (Franklin & Snow, 2005).  
  
Figure 14: Molecular structure of Tetracycline. 
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ANTIBIOTIC RESISTANCE  
The problem with resistance has coexisted together with antibiotics ever since their discovery 
and continues today, to be a major problem for the treatment of infections. In order for 
resistance to effectively flourish, a heterogeneous population of bacteria is required, in which at 
least one bacterium have the genetic build that allows survival after exposure to antibiotic. This 
will give the selective pressure, with susceptible bacteria being killed and the tolerant bacteria 
being able to proliferate, that allows for the potential spread of resistance genes (Alanis 2005).  
Intrinsic resistance, often used interchangeably with insensitivity, refers to resistance against 
antibiotics that relates to innate structures or components of the bacteria that confers the 
bacteria tolerant against certain antibiotics. Examples of innate resistance include the 
mycoplasma which have no cell wall, thereby being resistant against cell wall targeting 
antibiotics and P.aeruginosa, which have inefficient porins and low permeability of the outer 
membrane, due the dense LPS, thereby severely inhibiting uptake of most drugs (Franklin & 
Snow, 2005). Together with a limited uptake of drugs, some bacteria also intrinsically have 
different varieties of multidrug-efflux pumps, which continuously pump out harmful 
components, in some cases including antibiotics.  
AQUIRED RESISTANCE 
Susceptible bacteria can, by the means of 
spontaneous mutation or by acquiring resistance 
genes, become resistant to a given antibiotic. 
However, spontaneous mutations will only rarely 
result in widespread resistance, without exposure 
to antibiotics to mediate the selective pressure for 
the propagation of resistance genes. The genes that 
confer resistance can be located both on the 
chromosome but more frequently on plasmids and 
is often found in mobile regions of DNA, such as 
transposons that facilitate gene transfer between 
bacteria (Kumar & Scweizer 2005). The means, by 
which resistant genes are exchanged between 
individual bacteria, can be classified into three 
primary mechanisms, collectively known as horizontal gene transfer [Fig. 15], (Alanis, 2005). 
The most important and widespread mechanism of transfer is conjugation. This process 
Figure 15: Mechanisms of horizontal gene transfer. 
Edited from Levy & Marshall 2004 
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involves the transfer of mobile genetic elements such as transposons or plasmids, and requires 
the exchanging bacteria to be in close contact to allow the genetic transfer via sex pilus (Alanis, 
2005). Transformation is the process, in which bacteria take up free DNA, usually from dead 
bacteria and incorporates it into its own genome. Bacteria can, in response to changes in the 
environment, change into a state of competence which allows for uptake of exogenous DNA, 
although only some bacterial species are naturally capable of this maneuver (Alanis, 2005). 
Transduction is the transfer of DNA mediated by different vectors, usually bacteriophages. 
Bacteriophages will infect bacteria and thereby inject its DNA, which can encode resistance and 
incorporate it into the bacterial genome. Because of the specificity of bacteriophages, it is 
unlikely that genes will be exchanged between distant related bacteria (Alanis, 2005). These 
mechanisms altogether make it possible for bacteria, which are not necessarily close related, to 
exchange genetic material conferring various resistances against antibiotics, which in recent 
years has lead to propagation of resistant bacteria, at least in part because of the selective 
pressure mediated by excessive use of antibiotics.    
RESISTANCE MECHANISMS 
The transfer of resistance genes encodes various components needed for the biological 
strategies applied by bacteria to counteract the effects of antibiotics [Fig. 16], which will be 
outlined in the following section. Given the fact that many antibiotics are derived from bacteria 
and their unique ability to adapt, it is of little surprise that enzymes, specially designed for the 
breakdown or inactivation of various antibiotics exists. One example is the β-lactamase 
mediated resistance against β-lactams, which is probably the most pervasive with more than 
1000 unique β-lactamases identified (Davies & Davies, 2010). β-lactamase will upon interaction, 
cleave the β-lactam ring thereby rendering the drug inactive (Fisher et al., 2005). Because of the 
intense use of different kinds of β-lactams, it has become an evolutionary advantage to harbor 
β-lactamases with broader spectrum of activity, including activity against cephalosporins, 
thereby promoting the emergence of ESBL (extended-spectrum-beta-lactamase) strains, which 
are resistant to the far majority of β-lactam antibiotics (Fisher et al., 2005). 
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In addition to the trouble caused by enzymatic inactivation of antibiotics, mechanisms of driving 
compounds out of bacteria also hampers the effectiveness of antibiotics. Antibiotics that exert 
their activity by inhibition of cellular processes inside the bacteria rely on maintaining a 
concentration within the bacteria that allows for effective inhibition. This can be counteracted 
by efflux pumps that actively drive antibiotics out 
of the cell, although efflux obviously needs to 
exceed the capacity of the influx to bring resistance 
into effect. Efflux pumps can either be 
constitutively expressed or up regulated in 
response to the presence of antibiotic (Kumar & 
Scweizer, 2005). Efflux pumps are considered the 
dominant resistance mechanism against 
tetracycline and to a lesser extent against 
fluoroquinolones. Additionally, the inhibitory 
action of many antibiotics relies on great affinity 
against bacterial molecules. This evidently makes 
the drugs vulnerable to alterations in the bacterial 
target. Even small changes in the target site can 
render antibiotics ineffective demonstrated by 
mutations in gyrase, PBPs and ribosomal 
alterations, all resulting in resistance to 
fluoroquinolones, penicillins and aminoglycosides 
and tetracyclines, respectively.  
The overwhelming problems related to increasing resistance against conventional antibiotics, 
with no apparent solution in the horizon, strengthens the need for coming up with novel 
alternatives for bacterial intervention which has spawned intense research into AMPs, which 
will be discussed next, as possible lead structures. 
  
 
Figure 16. Biological mechanisms mediating 
resistance against antibiotics. Wright, 2010 
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ANTIMICROBIAL PEPTIDES 
STRUCTURE AND CLASSIFICATION 
As previously addressed, AMPs have been isolated from a wide range of organisms and vary in 
their biological effect from antimicrobial to immune modulators. Furthermore, various AMPs 
have been shown to possess antifungal and anti-viral activity but this thesis will focus on the 
antibacterial activity of AMPs. The variety in origin and biological effect is reflected in the 
characteristics of AMPs having a great deal of diversity, in both primary and secondary 
structure, probably explaining their evolutionary success (Hale & Hancock, 2007). There are a 
number of structural similarities that apply for most AMPs, usually being relatively short, 
ranging from 12-50 amino acids, carrying a net positive charge of +2 to +9 and having a distinct 
proportion of hydrophobic residues (Jenssen & Hancock, 2009). Further classification of AMPs 
are made on the basis of the secondary structure, which ranges from the two most abundant α-
helical and β-sheet, to extended structures together with loop structures which are rare. 
Examples of α-helical peptides include human isolated LL-37 and Magainin isolated from frog; 
β-sheet peptides encompass the human α- and β-defensins, and an example of a peptide with an 
extended structure is bovine isolated Indolicidin, used in this study as a reference peptide, [Fig. 
17], (Hancock & Sahl, 2006). In addition, the peptide Melittin 
(GIGAVLKVLTTGLPALISWIKRKRQQ), isolated from bee venom, which is a well-known non-
selective lytic peptide (Shai, 2002) was used as a control for membrane disruption and α-helical 
secondary structure. The secondary structure that AMPs display, is often only found in the 
Figure 17: Secondary structure of the α-helical LL-37, extended structure of Indolicidin and the β-sheet structure of α-
Definsin serving as examples of AMPs from different structural classes. Adapated from Hancock & Sahl, 2006. 
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proximity to lipid-like environments whereas most display a rather unstructured arrangement 
in hydrophilic suspension. When AMPs interact with lipids, and thereby also membranes, they 
are often seen to adapt an amphipathic structure which in most cases has been identified as 
significant for antibacterial activity (Friedrich et al., 1999). Adapting an amphipathic structure, 
translates into separating the hydrophobic and hydrophilic parts of the peptides into different 
patches of the secondary structure, to allow for interaction with both the polar headgroups of 
lipids and the hydrophobic lipid tail (Melo et al., 2009). 
The different mode of microbial inhibition has inspired classification of AMPs into peptides with 
a direct antibacterial effect and peptides with immune modulation as their primary hallmark, 
designated antimicrobial peptides and host defense peptides, respectively (Wieczorek et al., 
2010, Hancock & Sahl. 2006; Scott et al., 2007; Jenssen & Hancock 2009). In that context, most 
peptides isolated from natural sources have a rather modest direct antibacterial effect, and as a 
result should be characterized as host defense peptides (Wieczorek et al., 2010, Jenssen et al., 
2006). Examples of natural AMPs, with a direct antibacterial activity, include the bacterial 
derived antibiotic Polymyxin B and the lantibiotic Nisin used in food preservation (Hancock & 
Sahl. 2006). Interestingly, some AMPs have overlapping effects being, both immune modulating 
and direct antibacterial (Easton et al., 2009), which should be kept in mind when evaluating the 
therapeutic potential of peptide candidates, although the immune stimulating capabilities of 
peptides are not within the scope of this thesis.  
MECHANISM OF ACTION 
Regardless if the target of AMPs is intracellular or the bacterial membrane itself, they all depend 
on initial contact with the bacterial outer envelope (Jenssen et al., 2006). The interaction with 
AMPs and the outer membrane structures of bacteria is thought to rely on electrostatic 
attraction between the positively charged AMP and the negatively charged LPS and techoich 
acid for gram-negative and gram-positive bacteria, respectively. Additional features that 
facilitate AMP attraction to bacteria are the transmembrane potential of bacteria around –120 
mV and the composition of the bacterial membrane which harbors a substantial fraction of 
negatively charged lipids (Fjell et al., 2012). Conversely, most Eukaryotic cells have membranes 
that are distinctly different in their composition by composing of zwitterionic and neutral 
phospholipids thereby not mediating considerate electrostatic attraction towards AMPs. 
Furthermore, Cholesterol is an important component of many eukaryotic membranes and is 
thought to stabilize membranes (Wessman, et al 2008), thereby counteracting potential 
membrane disrupting effect of AMPs against most eukaryotic cells. The transition from 
interaction at the surface of the bacteria to gaining access to the cytoplasmic membrane is not 
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characterized in detail (Brogden, 2005) but is hypothesized to rely on hydrophobic interactions 
for gram-negative bacteria (Jenssen et al., 2006). As AMPs can act both as membrane 
disintegrating compounds and have intracellular targets, they can both traverse the membrane 
without significant effect and disturb membrane integrity in various ways depending on the 
peptide. The exact nature of membrane perturbation exerted by AMPs, have been a long-lived 
matter of debate and several models have been proposed but it would seem that it is hard to 
limit the diverse group of AMP, to act within the framework of a uniform model (Melo et al., 
2009). However, different models outlining the membrane permeabilizing effect of AMPs have 
become widely accepted, [Fig. 18], although they are primarily applied to the membrane 
interactions of α-helical peptides (Jenssen et al., 2006). Common for all the mechanisms, is that 
membrane disruption only comes into effect when a threshold concentration of peptides are 
present (Melo et al., 2009). One mechanism is denoted the Barrel-stave model [Fig. 18A], where 
peptides, following initial membrane binding, re-orientates perpendicular to the membrane and 
aggregates to form pores in the phospholipid layer, taking advantage of their amphipathic 
structure with the hydrophobic parts interacting with the lipids of the membrane whereas the 
hydrophilic regions line the lumen of the pore (Brogden et al., 2005: Yeaman & Yount, 2003; 
Jenssen et al., 2006). A somewhat different mechanism of membrane disruption, is described as 
the carpet mechanism [Fig. 18B], where peptides binds parallel to plane of the membrane. Upon 
reaching threshold concentration, the peptides will disrupt parts of the membrane to break off 
into micelles, also known as a detergent-like effect, which will cause local membrane disruption 
(Jenssen et al., 2006; Brogden, 2005). Finally, the toroidal pore model [Fig. 18C] outlines how 
peptides insert perpendicularly into the membrane and simultaneously induce the membrane 
to bend inwards to form pores consisting both of peptides and hydrophilic lipid head groups 
(Brogden, 2005; Yeaman & Yount, 2003; Jenssen et al., 2006). All of these models have the 
common feature of relying on the amphipathic structure, adapted in contact with lipids, to allow 
interaction with both the polar head groups and hydrophobic acyl chain of lipids.  
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THERAPEUTIC POTENTIAL  
Despite the fact that wide-spread resistance against AMP has not been observed, some bacteria, 
either intrinsically or adaptably, make use of various strategies to prevent the effects of AMPs 
(Teixeira et al., 2012). Modification of the outer entities of the cell envelope are examples 
hereof, where the negative charge of both LPS (Gunn & Miller, 1996, Ernst et al., 2001) and 
Techoich acids (Otto, 2009), by various modifications, have been diminished thereby decreasing 
the electrostatic attraction of AMPs. In addition, the composition of membrane lipids has been 
observed to change in some bacteria either by decreasing the proportion of negatively charged 
lipids (Hachmann et al., 2011) or by modifying some lipid entities with the addition of Lys 
(Peschel et al., 2001), both decreasing the negative charge of the membrane and thereby the 
affinity of AMPs . Other observed mechanisms include degradation of peptides by proteases or 
efflux pumps preventing inhibitory concentrations to manifest at the membrane (Teixeira, 
2012).  
Figure 18: Model for membrane permeabilizing exerted by AMPs. All of the depicted models require a threshold 
concentration of AMP for membrane permeabilization to occur. A: Barrel-stave pore formation by peptides interacting 
and forming perpendicular pores in the phospholipid membrane. B: Carpet mechanism where peptides orient themselves 
parallel to the membrane and disperse the membrane in a detergent-like manner. C: Torodial-pore formation by peptides 
inducing less defined pores where both peptides and phospholipid line the lumen of the pore. Edited from (Melo et al. 
2009) 
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Resistance against AMPs might seem worrying, since the great interest into investigation of 
AMPs as new lead structures for bacterial intervention, originate from the increasing problem of 
resistance against antibiotics but there are a number of features of AMPs that holds promise for 
them to be an important part of the continuing battle against infections. As AMPs are so 
abundant throughout the animal kingdom, it is conceivable to think that they have co-existed 
alongside bacteria for millions of years and the development of wide-spread resistance is yet to 
be reported (Fjell et al., 2012). Furthermore, the fast induced killing mediated by most lytic 
peptides as a result of interaction with the bacterial membrane, it has been suggested that wide 
spread resistance is less likely to occur (Ryge et al., 2008) because it would require considerate 
and costly rearrangement of the bacterial membrane (Kraus & Peschel, 2006). Also, most active 
AMPs display a somewhat broad-spectrum activity including activity against strains of bacteria 
that are resistant to conventional drugs (Straus & Hancock, 2006). Most importantly, AMPs have 
a molecular build-up which is rather different from conventional antibiotics, which adds new 
molecular entities to a decreasing pool of effective molecular structures against bacteria. 
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EXPERIMENTAL SECTION 
Given the fact that MIC tests are carried out in a 96-well microtitter plate format, and the results 
from the MIC tests comprise the basis for all the other experiments, the majority of the 
experiments are carried out in 96-well format to make the conditions from the different 
experiments comparable. Furthermore, most of the experiments are carried out with the 
Escherichia coli strain ATCC 25922 as this is an established reference strain for antimicrobial 
testing (Wiegand et al., 2008) and has a biosafety level of 1 which minimizes the need for 
precautionary actions while conducting the experiments.   
MATERIALS  
Bacterial strains: Escherichia coli ATCC 25922, Pseudomonas aeruginosa PAO1 ATCC 15692, 
Pseudomonas aeruginosa PAO1 strain H1001 (fliC::luxCDABE), Staphylococcus aureus ATCC 
29213.  
Antibiotics: Ampicillin sigma Cat no: A9518, Ciprofloxacin, sigma Cat no: 17850, Tetracycline 
Cat T7660, Tobramycin Sigma Cat no: T4014, Polymyxin B Sigma Cat no: 92301.  
Calcein, Sigma C0875, Mueller Hinton broth, Sigma, Cat no 70192, 96-well polypropylene 
microtitter plates (Cat. No. 3879, COSTAR), 96-well flat bottomed polystyrene Greiner plate 
(REF 655101). DMEM+Glutamax media, Invitrogen, cat no 32430-027, LIVE/DEAD® BacLight ™ 
Bacterial Viability Kit, L7012 (Invitrogen), POPC (770557), POPG (770257) and Cholesterol was 
acquired from Avanti Lipids.  
 GN-peptides were synthesized using solid phase Fmoc chemistry, with amidation on the 
carboxyl end, purified to a purity >95% using reversed phase HPLC and analyzed by mass 
spectrometry, before they were handed over to me. Bac-peptides were acquired from GenScript 
which guaranteed >90% purity. 
MIC TESTING 
The antimicrobial efficacy of the different peptides was tested using a serial dilution titration 
method, to determine the peptides minimal inhibitory concentration (MIC) against the different 
pathogenic bacterial strains. The MIC assay was essentially done according to (Wiegand et al., 
2008) and performed in sterile 96-well polypropylene microtitter plates (Cat. No. 3879, 
COSTAR). Overnight (ON) cultures were prepared by inoculating 5 mL of Mueller Hinton (MH) 
broth and left over night at 37°C in a water bath with shaking. The ON culture was diluted 1:50 
in fresh MH broth and allowed to grow until an OD600 of 0,4  had been reached. Finally, a 500-
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fold dilution of the bacterial suspension was made to reach a final concentration in the range of 
2-8×105 cfu/ml. 10 µl of a 2-fold peptide dilution series or antibiotic were transferred to sample 
wells and MH broth was used for sterility control and growth control was bacterial suspension. 
The final volume in all wells was 100 µl. The microtitter plate was then sealed with parafilm and 
placed at 37°C for 18 hours. The MIC 
concentration was scored as the lowest 
concentration with no visible growth after 18 hour 
incubation [Fig. 19]. The MIC results are given as 
the median value of at least 3 independent 
experiments. The concentration of the bacterial 
suspension added to the plate, was checked by 
plating a 500x dilution in duplicate on LB agar 
plates. 
 
HEMOLYSIS ASSAY 
  
To address the potential lytic effects that the peptides would have on red blood cells (RBC), a 
hemolysis assay was set up [Fig. 20]. 5 ml of freshly drawn human blood with EDTA was 
transferred to 50ml centrifugation tubes and 45 ml of 0,9% NaCl was added. The sample was 
centrifuged at 1500 rpm for 5 minutes and the supernatant was removed. The wash step was 
repeated twice with 0,9 % NaCl, after which the supernatant was clear. The sample was then 
stored at 4°C. The assay was carried out in sterile 96-well polypropylene microtiter plates 
(COSTAR Cat. No.3879). A two-fold 
dilution series of peptides was added 
together with 50 µl of RBCs giving a total 
volume of 125 µl. As a control for 100 % 
lysis of RBC, 1% Triton-X 100 was added 
and sterile 0,9% NaCl was added for 
baseline adjustments. The GN-peptides 
were tested in the range of 400 to 3,13 
µg/ml and the Bac peptides were tested in 
the range of 1000 to 15,6 µg/ml. The plate was incubated with shaking for 1 hour at 37°C, 
before being centrifuged at 1000 rpm for 5 minutes. 50 µl of the supernatant was transferred to 
Figure 20: Hemolysis assay of GN-peptides with 1% Triton-X 100 
as control. Decreasing concentrations from top to bottom. 
Triton-X 100 samples to the far right. 
 
Figure 19: MIC testing of peptide GN-2 to GN-6 
against E.coli ATCC 25922. Decreasing concentrations 
from left to right, illustrating growth and no growth. 
 
34 
 
a flat bottomed 96-well Greiner plate with 100 µl 0,9% NaCl in all wells. Absorbance at 414 nm 
was then measured in a multi-detection microplate reader Synergy HT.  
MTT ASSAY  
The toxic effect of the peptides that extended beyond lysis of RBCs was investigated using the 
MTT assay. The assay is based on the addition of the slightly yellow MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), which will be reduced by cellular 
reductases to purple formazan crystals, [Fig. 21]. The degree of conversion to formazan crystals, 
is directly related to metabolic activity of the living cells and the assay can therefore be used to 
determine the cytotoxic activity of a given compound. The MTT compound is reduced by 
different intracellular reductases with NADH being the dominant reductant in mammalian cells 
(Berridge et al 2005).  
 
 
 
  
  
  
Hela WT cells were cultured in DMEM media supplemented with 10% FBS and 1% pen/strep 
using standard techniques. The cells were passaged at least 2 times before being used in the 
assay, to ensure logarithmic growth. At about 80 % confluency, cells were harvested, quantified 
and 10.000 cells were seeded in a 96-well microtitter plate. The cells were placed in a 
humidified 5% CO2 atmosphere at 37°C for 24 hours. Media was aspirated by inverting onto 
tissues and the cells were washed with PBS w/o Ca2+ and Mg2+. 100 µl of peptide diluted in 
DMEM media was added and the cells were incubated in a humidified 5% CO2 atmosphere at 
37°C for 1 hour. The cells were again washed with PBS w/o Ca2+ and Mg2+ before loading 100 µl 
of 500 µg/ml MTT dissolved in PBS w/o Ca2+ and Mg2+. The cells were incubated 90 minutes in a 
humidified 5% CO2 atmosphere at 37°C. MTT solution was aspirated and 100 µl of DMSO was 
added to dissolve the formazan crystals before incubating 5 min at 37°C. The absorbance at 540 
nm was read in a multi-detection microplate reader Synergy HT. Viability control was assigned 
to samples with only Hela WT cells and DMEM media and 0 % viability was assigned to samples 
with 1 % added Triton-X-100 instead of peptides. The assay was done 3 times with dublicates 
Figure 21: Cellular reduction of MTT to purple MTT Formazan, indicative of metabolic activity of 
cells. Edited from Stockert et al. 2012 
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and results are the mean of these. Concentrations giving a 50% reduction (IC50) in metabolism, 
was calculated using equation (1) in Graphpad Prism.  
  
   
                                
                              (1) 
SYNERGY TESTING 
To investigate potential synergy effect between antibiotics and the most active peptides, a 
synergy assay was made based on the checkerboard titration method. The assay was carried out 
for P.aeruginosa PA01 ATCC 15692 , E.coli ATCC 25922 and S.aureus ATCC 29213 with the 
conventional drug of choice for each bacteria together with peptides. ON culture was diluted 
1:100 in fresh MH broth and allowed to grow to an OD600 of 0,1 at 37°C with shaking to ensure a 
uniform bacterial population. The suspension was then diluted 1:100 to give a concentration of 
bacteria that should correspond to 5x105 cfu/ml and 90 µl was added to all wells except for 
sterility control. 5 µl of both peptide and antibiotic, at 20x the desired test concentrations was 
added to all wells individually. The tested concentrations of both antibiotic and peptides ranged 
from 4 x MIC to 
 
 
 x MIC. Inhibition was scored as no visible growth after 18 hour incubation. 
Synergy was based on the calculation of Fractional inhibitory concentration (FIC) index, using 
equation (2), where ≤ 0,5 is considered synergy, >0,5 to ≤1 additive, >1 to  <4,0 indifferent and  
≥ 4,0 antagonism (Yan & Hancock, 2003) 
          
 
    
  
 
    
    (2) 
 
A:  MIC of antibacterial in combination 
MICA:  MIC of antibacterial alone 
             
B:        MIC of antibacterial in combination 
MICB:  MIC of antibacterial alone 
  
36 
 
CFU COUNTS 
 
In order to obtain a greater understanding of whether the peptides acted in bacteriocidal or 
bacteriostatic manner, and to establish a time-course of the inhibitory event, colony forming 
units (CFU) counts were monitored for 180 minutes, following peptide exposure at 
concentration corresponding to 1x, 2x and 4xMIC. ON culture of E.coli ATCC 25922 was diluted 
1:50 in fresh MH broth and regrown to an OD600 of approximately 0,4 before diluting to a 
turbidity of 0,1 and loading 135 µl into wells of a flat bottomed 96-well Greiner plate. Finally, 15 
µl of peptide solution corresponding to a final concentration of 1x-, 2x- and 4xMIC  was added  
for a total volume of 150 µl. Bacterial suspension was added as growth control  and extracted at 
the same time points as the peptide treated sample. Two plates of MH broth and 0,9% NaCl 
served as sterility control. Before loading of the wells, 10 µl of the bacterial suspension was 
extracted in duplicates and diluted before plating on LB agar plates to establish the starting 
inoculom. The procedure of removing 10 µl from the wells and subsequent dilution in ice cold 
0,9% NaCl was repeated for every sample at each time point. Between extractions, the 
microtitter plate was sealed and placed at 37°C. LB agar plates were incubated for 18 hours at 
30°C and colonies were counted. Only plates with less than 400 CFU was included. If no visible 
growth was observed on plates, they were left for another 18 hours at room temperature to 
reveal potential slow growing colonies. The presented results are the mean of 3 independent 
experiments.  
OPTICAL DENSITY MEASUREMENTS 
To start of the investigation on the mechanism of action of the peptides, the most active 
peptides were tested against E.coli ATCC 25922, together with four different antibiotics. Each of 
the antibiotics has different bacterial components as their target and a comparison with the 
peptides should therefore give an indication of the bacterial target of the peptides. ON culture of 
E.coli ATCC 25922 was diluted 1:50 in fresh MH broth and regrown to an optical density (OD) at 
600 nm of approximately 0,4 before diluting with fresh MH broth to a turbidity of 0,1. This 
rather high bacterial concentration which is roughly a 100-fold higher than the one used in the 
MIC experiments was necessary to give measurable gap between the baseline and the tested 
wells. Due to the nature of the experiment it was necessary to change the microtitter plate to a 
flat bottomed polystyrene Greiner plate (REF 655101) which is compatible with optical density 
measurements. 10 µl of peptide or antibiotic solution was added to wells, before loading 90 µl of 
bacterial suspension, thereby giving a final volume of 100 µl. For both peptides and antibiotics, 
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concentrations corresponding to 1x-, 2x- and 4xMIC were used. Furthermore, antibiotic samples 
were run in duplicate whereas the peptides were not, to minimize the use of peptide due to 
limited stocks. Immediately after addition of bacteria to the wells, the optical density at 600 nm 
was measured, with a multi-detection microplate reader Synergy HT, every 8 minutes for 5 
hours, to give a correlation of optical density and time for both peptides and antibiotics. The 
kinetic protocol for the multi-detection microplate reader Synergy HT, was designed to shake 
the plate for 5 seconds at maximum intensity before every reading and the temperature was set 
to 37°C, to give the best possible growth conditions for the bacteria. The readings were baseline 
corrected against wells with only MH broth. Comparison between a standard 
spectrophotometer, with a cuvette length of 1 cm, and the readings obtained from the plate 
reader showed a difference with 5-fold lower readings from the plate reader (data not shown). 
In order to make readings meaningful, in relation to the correlation between optical density and 
concentration of bacterial cells, the readings from the plate reader was multiplied with a factor 
of 5. 
LUMINESCENCE SCREENING 
To support the results from MIC testing and to establish an assay for future screening of 
peptides, the luminescence inhibition assay was employed, using GN-2 as a proof of concept. In 
this assay, the P.aeruginosa H1001 strain with a Tn5-luxCDABE transposon inserted into the fliC 
gene, which is constitutively expressed, was utilized. The assay was essentially performed in 
accordance to the protocol in Hilpert & Hancock, 2007. ON culture of strain P.aeruginosa H1001 
was diluted 1:100 and allowed to grow until an OD600 of 0,35 and then diluted 1:26 in 0,1M Tris-
buffer pH 7,3 20mM glucose. 45 µl of bacterial suspension and 5 µl of a 2-fold peptide dilution 
were subsequently added to the wells of a flat bottomed Greiner plate with shielded wells. The 
plate was, immediately thereafter, sealed with parafilm and transferred to a multi-detection 
microplate reader Synergy HT, for measurements of luminescence every 10 minutes over the 
course of 10 hours at 37°C. Background luminescence was established from wells with only 50 
µl of 0,1M Tris-buffer pH 7,3 20mM glucose and growth control was derived from wells, with 
only 50 µl of the bacterial suspension. The assay was later manipulated after the concept had 
been proven to work. More specifically, the diluent was changed to investigate the effect of 
isotonic salt, Ca2+ and Mg2+ on the peptides ability to inhibit growth. This was done, by 
supplementing the original diluent 0,1M Tris-buffer pH 7,3 20mM glucose, with various salt 
components or by supplementing Hanks Balanced salt solution (HBSS) with 20mM glucose.  
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FLOW CYTOMETRY 
Flowcytometry experiments was included, to investigate the peptide effect on both bacterial 
DNA content and change in cell size after exposure with peptides. In order to be able to follow 
the changes over time, samples were extracted at 0, 20, 40, 80, 120 and 180 minutes. ON culture 
of E.coli ATCC 25922 was diluted 1:50 in fresh MH broth and allowed to grow until an OD600 of 
0,1 had been reached. The suspension was then diluted 1:10 in fresh MH broth and regrown to 
an OD600 of 0,1 to ensure a uniform bacterial population. 90 µl of bacterial suspension was 
loaded into a flat bottomed 96-well Greiner plate for peptide and antibiotic samples and 100 µl 
for control samples. After extraction of the zero sample, 10 µl of peptide solution corresponding 
to 1x and 4x the MIC concentration was added for a total volume of 100µl. Two wells were 
loaded for each treatment to ensure enough bacteria for the flow cytometry analysis. 
Immediately after extraction, the contents of two wells were transferred to a single E-tube and 
put on ice. The plate was placed at 37°C between extractions. The samples were, whenever 
appropriate during the experiment, centrifuged at 10.000x g for 5 min at 4°C. The supernatant 
was then carefully removed and the cells were resuspended in 100 µl 10mM Tris HCL pH 7,4 
and 1000 µl 77% Ethanol was added before storing the samples at 4° C for later analysis. The 
Rifampicin/Cephalexin samples were prepared in the same way as the other samples with the 
exception that the 200 µl from the wells were transferred to an E-tube with 45 µl mixture of 
Rifampicin (300µg/ml) and Cephalexin (36µg/ml) and placed in a 37°C water bath for 2½ 
hours. Simultaneously, the OD600 was measured approximately every 25 minutes in a multi-
detection microplate reader Synergy HT to monitor bacterial growth. The following day, the 
samples were centrifuged at 10.000x g for 5 min before gently removing the supernatant and 
adding 140 µl staining solution (90µg/ml Mitramycin and 20µg/ml Ethidium Bromide in 10 mM 
Tris pH 7,4, 10mM MgCl2). The samples where run on an A10 Bryte Flow Cytometer and when 
possible, 20.000 events were included in the analysis.  
LIVE-DEAD STAINING  
The LIVE/DEAD® BacLight ™ Bacterial Viability Kit, L70 2, was applied to peptide treated E.coli 
ATCC 25922, to investigate a visual indication of the membrane permeability cababilities of the 
peptides. This kit contains the SYTO9 green-fluorescent nucleic acid stain together with the red-
fluorescent Propidium Iodide (PI) stain. Despite the fact that both are nucleic acid stains, they 
differ both in their spectral capabilities and their capacity to penetrate bacterial membranes. 
SYTO9 is capable of staining both healthy bacterial cells and bacterial cells with damaged 
membranes, whereas Propidium Iodide is only able to penetrate bacterial cells with damaged 
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membranes. This means that when SYO9 is used alone, it will stain both live and dead bacteria 
green independent of membrane integrity. Propidium Iodide will only penetrate damaged 
membrane and suppress the green fluorescence mediated by SYTO9 of cells with damaged 
membranes. This allows for the use of these fluorescent dyes in conjunction to distinguish 
between cells with intact membranes which will appear green and dead or cells with damaged 
membranes will appear red (Invitrogen, 2004).   
 
ON culture of E.coli ATCC 25922 was diluted 1:100 in fresh MH broth and allowed to grow until 
an OD600 of 0,1. 10 µl of peptide solution corresponding to a final test concentration of 1x- and 
4xMIC was added to a flat bottomed polystyrene Greiner plate before loading 90 µl of bacteria 
suspension. 100 µl of bacterial suspension was used as a control. Each well corresponded to one 
time point for each individual treatment. The plate was placed at 37 °C and the samples were 
extracted at the indicated time points of 0, 10, 20, 40, 80 and 120 minutes and immediately put 
on ice. The samples were then centrifuged at 10000g for 5 minutes, the supernatant was 
removed and the pellet resuspended in 100 µl 0,9% ice cold NaCl, to remove interfering media 
components. 1 µl of staining solution was added and incubated for 15 min in the dark, before 
loading to agarose slips on microscope slides. Microscope slides where prepared by loading the 
slides with a 1% agarose solution, with salts to prevent osmotic lysis of the cells. Staining 
solution was prepared by adding 5 µl of 3,34 mM Syto-9 dye in DMSO (Compound A) and 5 µl of 
20 mM Propidium iodide in DMSO (Compound B) to 20 µl of sterile water. Samples were 
inspected with a Leica DM5000B microscope using a mercury lamp. A filter cube with excitation 
filters of 436, 495 and 580 nm and emission filters of 460, 535 and 630 nm was used to be able 
to detect both live and dead bacteria.     
LIVE-DEAD QUANTIFICATION  
To verify the findings from microscope pictures and to apply an assay that could characterize 
the membrane permeability of the entire bacterial population in the samples, the Live-Dead 
quantification was performed. The assay was essentially performed according to the 
manufacturer’s instructions. ON culture of E.coli ATCC 25922 was diluted 1:100 in fresh MH 
broth and allowed to grow until an OD600 of 0,1 had been reached. 2x1ml was transferred to E-
tubes and pelleted at 12000rpm for 8 minutes. One E-tube was resuspended in 1ml 0,9 % NaCl 
and the other was initially resuspended in 50 µl 0,9% NaCl to get the bacteria in suspension and 
then 950 µl 70% Isopropyl alcohol was added to kill the cells. The tubes were left on ice for 
minimum 1 hour with manual shaking approximately every 15 min. The tube with isopropyl 
alcohol was then pelleted at 12000 rpm for 8 minutes and resuspended in 1 ml 0,9% NaCl to 
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remove the isopropyl. 5 different ratios of live/dead bacteria were prepared according to the 
table below with a total volume of 400 µl for each to be able to make triplicates of each ratio. 
3x100µl of each suspension was loaded to individual wells, before measuring fluorescence on a 
multi-detection microplate reader Synergy HT to make the standard curve. 
 
 
   
 
 
  
The staining solution was prepared by adding 3 µl of both compound A and B, for each 1ml of 
distilled sterilized water and stored in the dark. 100 µl of staining solution was then added to 
each well and mixed by pipetting up and down several times, with the multichannel pipette and 
changing tips for every well. Bacterial samples with peptide was prepared by adding 10µl of the 
peptide in question and 90 µl of bacterial suspension with an OD600 of 0,1 to each well. The total 
volume of each well was transferred to pcr tubes (to increase the chance of getting a visible 
pellet) at the indicated time points and immediately put on ice and then pelleted at 12000 rpm 
for 8 minutes, before being resuspended in 0.9% NaCl and placed on ice again. The contents of 
each pcr tube was then added to individual wells of flat bottomed polystyrene 96-well Greiner 
plate and mixed with 100 µl staining solution. The samples were incubated in the dark for 15 
minutes before measuring fluorescence on a multi-detection microplate reader Synergy HT. 
Green fluorescence was excited at 485 nm and the emission detected at 528 nm, whereas the 
red fluorescence was excited at 530 nm and detected at 645 nm. Percentage of living cells was 
obtained by using equation (3) using the standard curve made from known ratios of live cells 
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ISOTHERMAL CALIROMETRY – ITC 
Investigation of the peptides potential to interact with LPS was done by utilizing Isothermal 
Titration Calorimetry (ITC). The concept of the assay relies on the fact that, upon binding of 
substances, heat is either generated or absorbed and this change in heat is recorded by the ITC 
device, which allows characterization of the binding. The ITC device has both a reference and 
sample cell [Fig. 22], filled with the diluent to be 
used in the study and sample solution, 
respectively. Ligand is titrated into the sample 
cell in defined aliquots, by the means of the 
injection needle and the change in heat, required 
by the ITC device to keep the temperature 
constant in the sample cell in comparison with 
the reference cell, during ligand titration, is 
recorded. This change in heat is either used to 
cool the sample cell, to counteract the heat 
generated from an exothermic reaction, or heat 
the sample cell in the case of an endothermic 
reaction taking place, in either case being 
proportional to the amount of binding. By applying the concentrations of both ligand and 
solution in the sample cell, determination of enthalpy (ΔH), entropy (ΔS), binding constants (KB) 
and reaction stoichiometry of the interaction, is ideally possible. In this study, LPS isolated from 
Pseudumonas aeruginosa PA01 was dissolved to 1mg/ml in PBS w/o Ca2+ and Mg2+. Due to the 
vast heterogenecity of LPS an anticipated molecular weight of 10.000Da was applied as the 
literature describes molecular weights of different LPS ranging from 4000Da (Rosenfeld et al 
2006) to 20.000Da (Srimal et al 1996). The peptides was diluted to 1 mM in PBS w/o Ca2+ and 
Mg2+. The ITC apparatus was meticulously cleaned and both peptide and LPS solutions were 
degassed under vacuum for at least 5 minutes, before loading into syringe and sample cell, 
respectively.  The settings were with few exceptions, 40 injections of 4 µl with spacing of 240 
seconds and an injection time of 8 seconds and baseline setting at 25 µcal. Furthermore, an 
1800 second delay was applied to get a steady baseline before injection of ligand. 
  
Figure 22: Schematic of ITC device with sample and 
reference cell together with injection needle. Adapted 
from Zhou et al. 2011. 
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LIPOSOME PREPERATION  
 
To elucidate the membrane penetration capabilities of the peptides, Large unilamellar vesicles 
(LUVs) mimicking bacterial membranes with entrapped calcein was prepared, to be used in the 
calcein release assay. Liposomes without calcein, mimicking both bacterial and mammalian 
membranes used in CD spectroscopy, to determine secondary structure was also prepared. The 
two lipids POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol) : POPC (1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine) was mixed in a molar ratio of 7:3 with a total weight of 6 
mg as a simple mimic of bacterial membranes and the lipids POPC:POPG:Cholesterol was mixed 
in a molar ratio of 5:3:2 as a simple mimic of mammalian membrane. The lipid mixture was 
concentrated on a rotary evaporator and washed 3 times with 99,9 % ethanol to remove 
residual organic solvents. The lipid mixture was then dissolved in 4 mL HEPES buffer (10mM 
HEPES, 150 mM KCL, 0,03 mM CaCl2, 0,01 mM EDTA, pH 7,4) with 20 mM calcein, for calcein 
containing liposomes and 10 mM Tris pH 7,4 for empty liposomes used for CD spectroscopy, 
followed by thorough mixing and sonication for 5 minutes to prevent aggregates. Subsequently, 
the lipid mixture was vigorously whirlmixed every 10 min over the course of 1 hour and finally 
left at room temperature for 1 hour, to allow the lipids to anneal. LUVs were prepared by 
extruding the lipid mixture through, two double stacked 100nm filters, a total of 10 times using 
a Nitrogen powered extruder. The calcein containing liposomes was put on Sephadex G-50 
columns to separate encapsulated calcein from free calcein and eluted with HEPES buffer. The 
size of the liposomes was verified to be approximately 110 nm with a narrow size distribution 
by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern,Worcestershire, UK). 
Malvern DTS v. 5.10 software (Malvern,Worcestershire, UK) was used for acquisition and 
analysis. By comparing the end volume with the starting volume, the dilution of the initial 
liposome concentration was estimated and that lead to the anticipation of a stock concentration 
of 971 µM of the liposomes. 
CALCEIN RELEASE 
Calcein release was done in a 96-well plates with shielded wells (MicroWell 96 optical bottom 
plate, NUNC, Roskilde,DK). 100 µl of peptide diluted in 10mM HEPES buffer was added to all 
wells except for background control in which 100 µl of 10mM HEPES was added. Preliminary 
measurements were made using a 5-fold peptide dilution series, to determine the range of 
activity and subsequent measurements were made with a 2-fold peptide dilution series. 
Immediately before measurement of leakage, 80 µl of 45 µM liposome suspension was added for 
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a final liposome concentration of 20 µM. Measurements were performed in a FLUOstar OPTIMA 
plate reader at an excitation wavelength of 485 nm and an emission wavelength of 520 nm over 
the course of 1 hour at 37°C. Maximum leakage of liposomes was acquired by lysis with 10% 
Triton and release following peptide exposure, was calculated using equation (4), where Fmax 
denotes fluorescence after addition of 10% Triton, F0 represents background fluorescence of 
liposomes and F designates the fluorescence intensity after peptide addition.  
               
     
        
   (4) 
CIRCULAR DICHROISM (CD) SPECTROSCOPY 
CD spectroscopy measurements were conducted to identify secondary structure of peptide 
under different conditions in hope of identifying a correlation between possible secondary 
structure and antibacterial activity or cytotoxicity.  CD measurements with peptides were 
performed using the prokaryotic membrane mimicking liposomes and mammalian mimicking 
liposomes described previously and also with 10 mM Tris buffer. CD spectra were obtained in 
the far UV spectrum (195-250 nm) with a Jasco J-715 CD spectrophotometer at room 
temperature with a N2-flow of 40 L min-1 using a 0.1 cm path-length quartz cuvette at a scan rate 
of 50nm/min at 1.0 nm intervals. The spectrophotometer was calibrated to read +190.4 ± 1 
millidegrees (mdeg) at a wavelength of 291 nm with a 1 cm path-length quartz cuvette using a 
0.6 mg/ml solution of Ammonium d-Camphor 10-Sulfonate, as prescribed by the manufacturer. 
Liposomes was added at concentration of 2 mM and peptides at 20 µM to obtain a lipid to 
peptide ratio of 100:1 as previously described (Bahnsen et al., 2012). The displayed CD spectra 
are the mean of 5 scans which are smoothed using a Savitzky-Golay routine and corrected for 
the relevant background contribution. CD spectra were converted into molar ellipticity by using 
the Kd2 algorithm on www.dichroweb.cryst.bbk.ac.uk,  which was also used to calculate the 
percentage of different secondary structure whenever the error limit of the algorithm made it 
possible.  
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RESULTS 
To make a coherent presentation of the results the purpose and concept of each experiment will 
be established prior to highlighting the major findings of each assay and whenever appropriate, 
compared to the literature. A detailed interpretation of the results and their significance is given 
in the Discussion section. 
DETERMINATION OF ACTIVITY 
 
BAC LIBRARY 
Initially, the previously described Bac8c (RIWVIWRR) peptide, optimized from isolated 
Bactenecin, was used as basis to design new peptide variants with improved activity. This was 
done by exchanging the third to the sixth amino acid in the original sequence with an Arg giving 
rise to 4 variants named Bac-1 to Bac-4, in an attempt to elucidate the effect of charge 
distribution. More variants were made by removing Val (Bac-5), and removing the second 
position Ile and Val (Bac-6) and finally Bac-7 was constructed by removing Trp, Val and Ile, in an 
attempt to make variants that could retain activity with a shorter length, [Table 2]. All variants 
were designed at the same time and it was therefore not possible to benefit from the activity of 
single variants to adjust the design of new ones.  
The selective antibacterial activity was assessed by using a serial dilution titration assay, to 
determine Minimal Inhibitory Concentrations (MIC) against reference strains of E.coli, S.aureus 
and P.aeruginosa, and by determining the highest concentration of peptide that induced less 
than 10 % hemolysis, designated as the hemolytic activity [Table 2]. MIC values of common 
antibiotics, with different bacterial targets, were also determined, both to verify the accuracy of 
the assay and also to identify MICs, to be used in killing kinetics and morphology studies. None 
of the Bac variants that were created displayed improved activity against the tested bacteria. 
The Bac-3 variant, where the 5’th amino acid Ile was substituted for Arg, was the variant with 
the best activity, although the MIC values were 2-3 fold higher in comparison with the parental 
peptide. When comparing the hydrophobic moment, a measure of amphipathicity, it becomes 
apparent that the variants with values close to Bac8c, are also the ones with best antibacterial 
activity, suggesting amphipathicity as an important feature within this library of peptides. The 
fact that none of the variants with a retained length of 8 amino acids and only Arg substitutions, 
could display similar activity, is a bit surprising but also supports the general perception that 
the ratio between charge and hydrophobic residues are critical determinants for antibacterial 
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activity (Matzuzaki, 2009;Jenssen et al 2006). On the other hand, you see improved Therapeutic 
Index (TI), especially for the Bac-3 variant [Table 2], which might be preferable over the 
parental peptide against E.coli, because of this feature. Furthermore, it would seem that activity 
is extremely dependent on chain length, at least when working with peptides of such small 
length, given that none of the variants with reduced chain length, had any detectable hemolytic 
activity or inhibitory action against the tested bacterial strains. Although the Bac8c variants 
generally showed little or diminished activity, it is worth noting that mediocre activity against 
E.coli was observed for the most active variants, whereas activity against P.aeruginosa was 
severely diminished or in most cases completely abolished and only weak activity against 
S.aureus was observed.   
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          Minimal inhibitory concentration, µg/ml 
   
 
Peptide 
 
Sequence 
 
Hydrophobic  
Moment 
 
       E.coli  
 
 
P.aeruginosa 
         
 
  S.aureus 
 
< 10 % Hemolysis 
          
 
Therapeutic Index 
Range 
 
Bac8c 
 
RIWVIWRR 
 
     4,4 
  
       6.25 
    
           6.25 
    
      12.5 
    
        125 
    
         10 - 20 
 
Bac-1 RIRVIWRR      4,1        25         > 100       50      > 1000          10 - 40 
 
Bac-2 RIWRIWRR      6,1        25         > 100       100      > 1000          10 - 40 
 
Bac-3 RIWVRWRR      5,1        12.5            50       50      > 1000          20 - 80  
 
Bac-4 RIWVIRRR      1,9    > 100         > 100    > 100      > 1000          — 
 
Bac-5 RIWIWRR      1,0    > 100         > 100    > 100      > 1000          — 
 
Bac-6 RWIWRR      3,5    > 100         > 100    > 100      > 1000          — 
 
Bac-7 RIWRR      6,8    > 100         > 100    > 100      > 1000          — 
Indolicidin ILPWKWPWWPWRR 
 
     1,2        25            100       12.5         100           4 - 8 
Ampicillin          4         (11)         > 64     (>183)       4        (11)   
Ciprofloxacin          0,05   (0,2)            0,2     (0,6)       0,4    (1,2)   
Tobramycin          0,78   (1,7)            0,1     (0,2)            
Tetracycline          1         (2,3)            8        (18)           
TABLE 2: Peptide characteristics, activity and toxicity 
 
Median MIC values of Bac peptides, Indolicidin and antibiotics in µg/ml against E.coli ATCC 25922, P.aeruginosa PA01 ATCC 15692 and S.aureus ATCC 29213 obtained by 3 repeated 
experiments. Due to their somewhat different molecular weight, MIC values of antibiotics are also given in µM, seen in brackets. Hydrophobic moment is a quantitative measure of 
amphipathicity calculated with HydroMCalc using the CCS scale. Hemolysis values are the mean concentration in µg/ml recorded over 3 experiments that induced less than 10% 
hemolysis. Range of Therapeutic index (TI) designates the lowest and highest value of TI which is calculated as the highest concentration that induced less than 10 % hemolysis divided 
by the median MIC value against individual bacterial strains 
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GN-LIBRARY 
As a result of the low antibacterial activity displayed by the Bac variants, another library of 
AMPs consisting of peptides designated GN-2 to GN-14, created by Fjell and colleagues, was 
investigated. This was done to identify peptides with a selective activity that could justify 
studies on the mechanism of action against bacteria. The original format of the GN-library, is the 
result of quantitative structure-activity relationship (QSAR) optimizations applied to two 
different starting libraries of peptides that were biased towards having amino acids typically 
found in AMPs such as Ile, Lys, Arg, Val and Trp (Fjell et al., 2011). One starting library had an in 
silico predicted activity that was good and the other had a moderate predicted activity. After 
numerous QSAR runs, simulating evolutionary development and optimization of peptide activity 
traits, the peptides that were predicted to be the most active from each starting library was 
selected. GN-2 to GN-6 originated from the active starting library and GN-8 to GN-14 originated 
from the starting library with a moderate predicted activity. The resulting library of GN-
peptides which are investigated in this study, all have a positive charge of +4 and uniform chain 
length of 9 amino acids and at least three Tryptophan residues, [Table 3].  
 
ANTIBACTERIAL ACTIVITY  
The ability of the GN-peptides to inhibit bacterial growth was evaluated by a serial dilution 
titration method, to obtain MIC values against E.coli, S.aureus and P.aeruginosa reference strains 
[Table 3]. Despite their many similarities, the antibacterial activity of the GN-peptides varies 
considerably, with MIC values ranging from 100 to 1,56 µg/ml against the tested bacterial 
strains. From reviewing the MIC values, it becomes apparent that the peptides GN-2 to GN-6, 
which originates from the same starting library, display potent broad spectrum activity against, 
both gram-positive S.aureus and gram-negative P.aeruginosa and E.coli. In comparison, the 
peptides GN-8 to GN-14, originating from a different starting library, for most of the peptides 
have comparable activity against E.coli but only display weak activity against S.aureus and 
P.aeruginosa. Of special interest is the potency of the GN-2 peptide, with MIC values of 3,13 
µg/ml for P.aeruginosa and S.aureus and 6,25 µg/ml for E.coli, and the remarkable low MIC 
value of 1,56 µg/ml for the GN-5 peptide against S.aureus. Increasing hydrophobic moment, a 
quantitative measure of amphipathicity, has previously been correlated with increasing 
bacterial activity (Teixeira et al., 2012) and the two most potent peptides, GN-2 and GN-4, have 
the highest hydrophobic moment suggesting amphipathicity as an important trait for 
antibacterial activity.   
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Hydrophobic moment is a quantitative measure of amphipathicity calculated with HydroMCalc using the CCS scale. Median MIC values of GN-peptides in µg/ml against E.coli ATCC 25922, 
P.aeruginosa PA01 and S.aureus ATCC 29213 obtained by 3 repeated experiments. Hemolysis values are the mean concentration in µg/ml recorded over 3 experiments that induced less 
than 10% hemolysis. Range of Therapeutic index (TI) designates the lowest and highest value of TI which is calculated as the highest concentration that induced less than 10 % hemolysis 
divided by the median MIC value against individual bacterial strains. IC50 values in µg/ml are calculated from the equation  Y=100/(1+10^((LogIC50-X)*HillSlope))) in Graphpad Prism based 
on the results from MTT assays performed on HelaWt cells.  
                  
             Minimal Inhibitory Concentration (µg/ml) 
 
 
   
 
Peptide 
 
Sequence 
 
Hydrophobic 
Moment 
 
       E.coli  
 
          P.aeruginosa 
   
          S.aureus 
 
       < 10 % Hemolysis 
 
  Therapeutic 
  Index Range 
 
 IC50 
 
 
 GN-2 
 
RWKRWWRWI 
 
       5,4 
 
       6.25 
 
                3.13 
 
           3.13 
 
                  100 
 
     16 - 32 
 
 
   47  
 GN-3 KWWRWRRWW        3,3        12.5                 25            6.25                   100       4 - 16 
 
   106  
 GN-4 RWKKWWRWL        5,5        6.25                 3.13            6.25                   100     16 - 32 
 
   37  
 GN-5 KKRWWWWWR        2.8        12.5                 6.25           1.56                   100       8 - 64 
 
   131  
 GN-6 RKRWWWWFR        2.8        12.5                 6.25           3.13                   100       8 - 32 
 
   97  
 GN-8 IWKRWWWKR        2.2        25                 100           50                > 400       4 - 16 
 
   199  
 GN-9 RIWKIWWKR        4.8        25                 25        > 50                > 400       8 - 16 
 
> 200  
 GN-11 IKWKRWWWR        3.4        12.5                 50           25                > 400       8 - 32 
 
> 200  
 GN-12  KWWKIWRWR 
 
       2.9        25                 12.5           12.5                > 400     16 - 32    173  
 GN-14  RLWKRWWIR        4.4        6.25                 100           25                   100       1 - 32  > 200  
 
TABLE 3: Peptide characteristics, activity and toxicity 
 
49 
 
HEMOLYTIC ACTIVITY  
The selectivity between mammalian membranes and bacterial cells was assessed by 
determining the hemolytic activity of peptides by exposing red blood cells (RBC) to increasing 
concentrations of peptides, using a serial dilution titration method. Lysis of RBCs results in the 
release of hemoglobin and the extent of RBC lysis is proportional to absorbance of released 
hemoglobin, measured at 414 nm. The hemolytic activity was defined as the highest test 
concentration of peptides resulting in less than 10 % hemolysis [Table 3]. When reviewing the 
data from the hemolysis assay, a strong correlation between activity towards bacteria and 
hemolytic activity was revealed, with the peptides being most potent against bacteria also 
displaying the highest degree of hemolytic activity. Due to rather potent activity for most of the 
peptides, a Therapeutic Index (TI) (highest test concentration that resulted in less than 10% 
hemolysis divided by MIC) in the range of 4-64 was observed for 9 out of 10 GN-peptides. In 
comparison, Bac8c demonstrated a TI range of 10-20 and the bovine isolated Indolicidin used as 
a reference peptide, had a TI range of only 4-8 illustrating that most GN-peptides have superior 
selectivity. It should be noted though, that the accuracy of the cutoff at <10% hemolysis, suffers 
from the big gap between 100- and 200 µg/ml concentrations of peptides. Consequently, a more 
precise presentation of the most interesting hemolysis results are given in [Fig. 23], revealing 
that a concentration of 200 µg/ml induces an increase in hemolysis that is roughly around 3 fold 
higher than what is observed at 100 µg/ml, suggesting that beyond a threshold concentration, 
RBC lysis escalates. GN-4 induces the greatest degree of hemolysis at 200 µg/ml and GN-2 exerts 
the highest degree of hemolysis at both 50 and 100 µg/ml [Fig. 23].  
Figure 23: The percentage of hemolysis at various concentrations of peptide. 100 % hemolysis was defined as the 
absorbance at 414 nm of the samples with 1% added Triton-X-100. Results are the mean of 3 independent experiments and 
error bars indicate SEM. 
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CYTOTOXICITY 
To give a more complete evaluation of the potential toxicity of the peptides against mammalian 
cells, a MTT assay with Hela cells was set up. This assay allows detection of more subtle effects, 
which together with the membrane permeabilizing effect of the hemolysis assay, will give a 
more precise determination of the toxic contribution towards mammalian cells exerted by the 
peptides. The assay relies on the cellular reduction of MTT to purple formazan crystals and the 
degree of formazan formation, accordingly correlates to metabolic activity of the Hela cells, 
indicative of viability. The results from the MTT assay revealed that the most potent peptides 
against bacteria were also the ones exhibiting the greatest metabolic inhibition of the Hela cells. 
Hence, GN-2 and GN-4, which have the same charge distribution in the primary structure, are 
the strongest inhibitors of metabolic activity in Hela cells, having calculated inhibitory 
concentrations giving a 50% reduction (IC50) in metabolism of 47 and 37 µg/ml, respectively 
[Table 3]. Details about the IC50 values are located in Appendix II. The IC50 values are generally 
consistent with the results from the hemolysis assay, in terms of correlation between bacterial 
activity and toxicity, with the peptides having the greatest hemolytic activity, also display the 
strongest inhibition of metabolism in Hela cells [Fig. 24]. One slight deviation between the 
hemolysis assay and MTT assay exists, with the GN-14 peptide, which had comparable 
hemolytic activity as the most potent peptides, also displays an IC50 above the detection limit of 
200 µg/ml, making the correlation between hemolytic activity and cytotoxicity against Hela 
cells less clear.  
Figure 24: Visualizing the viability of Hela wt cells after 1 hour of exposure to peptides. 100 % viability was defined as the 
absorbance of samples that were only treated with media. All values were baseline corrected with the value from 
samples with 0,1 % Triton. Results are the mean of 3 independent experiments and error bars indicate SEM. 
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The review of the selective activity of the 10 GN-peptides reveals that even though all of the 
peptides have the same length and charge, there is substantial variation in both their potency 
against bacteria and their cytotoxicity. A general trend that can be extrapolated from these data, 
is that potency against bacteria has a close correlation with cytotoxicity and hemolytic activity, 
although a meaningful selectivity between bacteria and mammalian cells is exerted by the far 
majority of the tested peptides.   
For further characterization of the mechanism of bacterial inhibition, the GN-2 and GN-6 
peptides were selected. GN-2 was chosen because of its pronounced activity against all tested 
bacteria and high TI of 16 to 32. GN-6, like many of the other peptides, have a rather potent 
activity and meaningful TI but stands out, due to its distinctive primary structure containing 
Phenylalanine and a patch of 4 consecutive Tryptophan, which prompted for a comparison with 
the somewhat different GN-2 peptide. Based on preliminary results, GN-2 was used in all assays 
and compared to GN-6 whenever possible. All of the peptides of the GN-library were included in 
assays when the workload of the assay allowed it.  
SYNERGY WITH ANTIBIOTICS 
The potential of having two or more antibacterials with different targets, that when 
administered together, reduces the concentrations needed for effective bacterial inhibition, 
either additively or synergistically, is hard to overlook. Not only would the decreased total dose, 
reduce the risk of adverse effects and by targeting multiple bacterial targets at the same time, it 
is reasonable to think that resistance is less likely to occur (Eliopoulos & Eliopoulos, 1988). In 
that perspective, potential synergistic effects of the peptides, in combinatorial exposure with 
antibiotics was investigated. This was done by using the checkerboard titration assay, where 
bacteria are challenged with both peptide and antibiotic at the same time, with concentrations 
ranging from 4xMIC to 
 
 
xMIC. The assay was evaluated by calculating the Fractional Inhibitory 
Index (FIC) from equation (2). In the event of a synergistic effect, the FIC would be below 0,5 
and an additive effect would result in a FIC of 1. A FIC below 0,5 translates into a 4-fold 
reduction of MIC of each compound in combination, thereby showing a synergistic effect, 
whereas a FIC of 1 indicates additive effect with a 2-fold reduction in MIC of each compound 
(Yan & Hancock, 2001). Conventional antibiotics, commonly used against the tested strains, 
were applied together with GN-2 and GN-6. This resulted in a FIC Index of 0,31, when used 
together with ampicillin against S.aureus and FIC indexes of 0,63 and 0,56 for GN-2 and GN-6 
against E.coli, respectively [Table 4]. This indicates a synergistic effect against S.aureus and an 
additive effect against E.coli, when used together with the, cell-wall acting agent, ampicillin. An 
additive effect of ciprofloxacin, acting on the DNA machinery is observed against E.coli for both 
peptides, whereas no cooperative effect was observed with Tobramycin. Given the propensity of 
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many AMPs to induce membrane disturbances, the additive and synergistic effects observed in 
this study, could be related to the peptides inducing increased permeability of the bacterial 
membrane, thereby increasing accessibility to intracellular targets of antibiotics, similar to 
(Giacometti et al., 2005).   
 
      Table 4: Synergy with antibiotics 
  GN-2 GN-6 
 P.aeruginosa  S.aureus  E.coli   P.aeruginosa  S.aureus  E.coli  
Tobramycin 2 NT NT  2 NT NT 
Ciprofloxacin NT NT 1  NT NT 1 
Ampicillin NT 0,31 0,63  NT 0,31 0,56 
FIC index of GN-2 and GN-6 against P.aeruginosa PA01, S.aureus ATCC 29213, E.coli ATCC 25922. FIC index of ≤ 
0,5 is considered synergy, >0,5 to ≤1 additive, >1 to  <4,0 indifferent and  ≥ 4,0 antagonism. NT denotes, not 
tested. 
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KILLING KINETICS AND MORPHOLOGY  
BACTERIAL VIABILITY 
Insight into whether the peptide induced bacterial killing or growth arrest was obtained by 
monitoring CFU counts for 180 minutes, following peptide exposure at concentration 
corresponding to 1x, 2x and 4xMIC. It is apparent that GN-2 exerts its antibacterial effect on 
exponentially growing E.coli, within a few minutes, displaying maximum effect after 80 minutes 
[Fig. 25]. The inhibition is clearly concentration dependent, although a higher concentration 
seems to be required for inhibition compared to MIC values, which could be explained by the 
starting inoculum that is 100-fold higher in this assay. The GN-6 peptide displays a very similar 
pattern of inhibition, with a slight indication of delayed onset of inhibition, while it should be 
noted that the MIC is 2-fold higher than that of GN-2. For both peptides, this assay illustrates the 
ability to reduce the number of CFU at concentrations, of 2x- and 4xMIC. It should be noted 
though, that the variation between experiments was quite high at 4xMIC concentration which is 
obvious from observing the error bars indicating standard error of the mean (SEM).   
 
 
  
Figure 25: Viability of exponentially growing E.coli ATCC 25922 following exposure to GN-2 and GN-6 peptides at 
concentrations corresponding to 1x, 2x, and 4xMIC, depicted in µg/ml. Displayed results are the mean of 3 
independent experiments and error bars indicate SEM. 
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OPTICAL DENSITY MEASUREMENTS 
Elucidation of bacterial inhibition exhibited by peptides was investigated by OD measurements. 
OD is a measure of bacterial mass, being fairly proportional to cell growth and experiments 
were carried out over the course of 5 hours with a starting inoculum of OD600 of 0,1. 
Conventional antibiotics, each having different bacterial targets, were included in hope of 
identifying a similar inhibitional pattern for the GN-2 and GN-6 peptides that could indicate the 
bacterial target of the peptides [Fig. 26 A].   
The control sample display somewhat exponential growth characteristics up until 120 minutes, 
where a rather remarkable decrease is observed [Fig. 26 B]. It is expected that the control 
sample, as the bacterial numbers increase, move towards stationary growth, thereby displaying 
stabilization in the OD readings but no apparent reason for the decrease in OD can be given, 
since the OD showed good reproducibility. Intriguingly, there is indication of reestablished 
growth after 4 hours, which leads to the assumption that the decrease in OD is unlikely to be the 
result of nutritional limitations and waste build-up. Both GN-2 and GN-6 peptides exert a clear 
concentration dependent inhibition of OD. The inhibition is most pronounced at 2xMIC for both 
peptides, showing clear deviation from the control already at 40 minutes followed by a decrease 
in OD, previously assigned to bacterial lysis in growth experiments (Pasotti et al 2011). The 
difference in growth inhibition at MIC exposure between GN-2 and GN-6 could indicate that, 
with addition at MIC and a starting bacterial load of OD600  0,1, the two peptides exert their 
antibacterial activity in different ways or with different potencies. Since no decrease in OD, 
indicative of cell lysis is observed, it seems conceivable to think that both peptides induce some 
 
Figure 26: Kinetics of antibiotics and peptides against exponential growing E.coli. Bacteria were grown in a 96-well 
polystyrene plate at 37°C with shaking every 8 minutes. Depicted curves are the mean of 3 independent experiments 
based on measurements every 8 minutes. A: Antibiotics are added at MIC, being Ampicillin (4µg/ml), Tobramycin (0,78 
µg/ml), Tetratcycline (1 µg/ml) and Ciprofloxacin (0,05 µg/ml). B: GN-2  is added at 6,25 and 12,5 µg/ml plus GN-6 at 
12,5 and 25 µg/ml corresponding to 1x and 2xMIC respectively against E.coli. 
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kind of metabolic disturbance, which halts bacterial growth at MIC level, whereas 2xMIC likely 
induce some degree of bacterial lysis.  
When comparing the growth characteristics of E.coli following peptide and antibiotic exposure, 
[Fig. 26 A], no distinct similarities can be identified and this does not allow any conclusion to be 
made about the bacterial target based on this comparison. 
LUMINESCENCE SCREENING 
To support the results from MIC testing and to establish an assay for future screening of 
peptides the luminescence inhibition assay was employed, using GN-2 as a proof of concept. The 
concept of the assay is based on the expression of the luxCDABE gene cassette as a reporter gene 
in P.aeruginosa H1001 (fliC::luxCDABE). 
The gene cassette encodes both a 
bacterial luciferase (luxAB) and a fatty 
acid reductase complex (luxCDE) that 
generates the substrate for the 
luciferase. The luciferase enzyme 
catalyses the oxidation of reduced 
flavin mononucleotide (FMNH2) which 
results in light emission, provided that 
the bacteria supply molecular oxygen 
[Fig. 27]. As FMNH2 levels inside the 
bacteria are dependent on the energy 
level, a drop in emitted light is 
equivalent to attenuation of the 
metabolism of the bacteria (Hilpert & 
Hancock, 2007). More specifically, a 
decrease in emitted light can be 
attributed to a drop in ATP levels 
which can be a result of metabolic disturbance or leakage of the ATP that is produced (Hilpert et 
al., 2005). When reviewing the results from the GN-2 challenged P.aeruginosa H1001 using 
glucose supplemented Tris as solvent [Fig. 28], a concentration of 3,13 µg/ml is sufficient to 
inhibit the luminescence 3-4 fold over the course of 10 hours, with signs of bacterial recovery 
after 6 hours. Since the bacteria added to the different wells were added from the same 
suspension, it is intriguing to see that the starting point of the control and peptide treated 
samples differ in the Tris sample. This would suggest that the peptide exert its effect within the 
Figure 27 Schematic of the luciferase gene cassette. Edited from 
Fletcher et al. 2007 
Figure 28:Luminescence of lux strain P.aeruginosa H1001 in 20mM 
Glucose supplemented Tris pH 7,3, following GN-2 exposure. 
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timeframe from sample addition to the first reading, which is a matter of a few minutes. The 
assay protocol (Hilpert & Hancock, 2007) recommends to use glucose supplemented Tris for the 
assay even though it is also stated that in some cases, it will be too optimistic in producing an 
accurate measure of the antibacterial effect of peptides. This is particularly relevant for peptides 
that are sensitive towards cation concentrations, which lead to the application of various 
glucose supplemented salt solutions, to evaluate the effectiveness of peptides in conditions 
mimicking physiological salt concentrations. As previously described, LPS molecules are 
stabilized by divalent cations such as Mg2+ and Ca2+ (Kotra et al., 1999) and in that perspective, 
the effect of these two divalent cations were also investigated. 
Analysis of the results from carrying out the assay with different salt solutions reveal that they 
affect the peptide ability to interfere with metabolism considerably [Fig 29]. Addition of either 1 
mM Mg2+ or Ca2+ to saline, roughly doubles the concentration needed to reach the same level of 
relative inhibition, when compared to the sample without either of these. It would seem that 
Ca2+ induce a dampening effect on the ability of GN-2 to inhibit luminescence that is more 
profound than Mg2+, because increase in luminescense is seen in the case of Ca2+ already at 60 
minutes [Fig. 29]. On the other hand, the difference between Mg2+ or Ca2+ is not sufficiently clear  
 
Figure 29: Luminescence inhibition, indicative of metabolic inhibition, of lux strain P.aeruginosa H1001 after addition of 
GN-2 at indicated concentrations. All depicted solvents are supplemented with Glucose to reach final concentrations of 
20mM. luminescence was recorded every 10 minutes in a Synergy HT plate reader at 37°C over the course of 10 hours. 
Graphs are made on the basis of 2 independent experiments. 
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to confidently differentiate between the effect of the two cations, to affect the interaction with 
P.aeruginosa H1001 and GN-2.   
HBSS is a balanced salt solution commonly used in cell culture owing to its composition of 
various salts, providing a good mimication of physiological conditions. Most importantly, both 
Mg2+ and Ca2+  are present in roughly equimolar concentrations of 1mM,  and HBSS also contain 
saline-like NaCl concentrations together with buffer capacity mediated by bicarbonate and 
phosphate. Evidently, the use of HBSS inhibits the GN-2 peptides ability to disrupt luminescence 
expression greatly, demonstrated by 3-fold increase in the concentration needed for obtaning 
the same relative decrease in luminescence in comparison with the saline sample (18,78 and 
6,25 µg/ml) respectively. As the peptides activity is even more attenuated in HBSS, compared 
with the saline samples with added Mg2+ and Ca2+, it suggest that other components besides the 
divalent cations account for the hampered effect, exerted by GN-2 under these conditions.   
In summary, this assay reveal the importance of cations and other salts in evaluting the effect of 
the GN-2 peptide  against P.aeruginosa H1001 and also fulfilled its secondary purpose of 
establishing an assay to be used in future screening of peptides.  
PEPTIDE EFFECT ON BACTERIAL MORPHOLOGY 
Insights into the effect of peptides on cell size and DNA content was investigated by the use of 
flow cytometry. The assay was done in microtitter format over the course of 3 hours with a 
starting inoculum of OD600 0,1 to ensure sufficient bacterial numbers for analysis. By treating 
bacterial cells with a mixture of the nucleic acid stains Mitramycin and Ethidium Bromide, 
fluorescence detected by the flow cytometry apparatus, corresponds to DNA content in cells and 
detected lightscatter is fairly proportional to cell size.   
The control samples decreases gradually in both size and DNA over the course of 3 hours [Fig. 
30], in agreement with previous observations (Walberg et al., 1997, A), ascribed to the bacterial 
population approaching stationary phase. For both GN-2 and GN-6, the addition of peptides at 
MIC  seem to induce a period of somewhat constant cell size up until 80 minutes, where a slight 
decrease in cell size sets in [Fig. 30]. Addition of either peptide at MIC have no pronounced 
effect on cell size, except for a slight indication of delaying the decrease in cell size which is also 
observed in the control samples. A more distinct effect on cell size is observed when the 
peptides are added at concentrations that correlate to 4xMIC concentrations, displaying a clear 
and rapid increase. The rather dramatic increase in cell size takes effect already after 20 
minutes and reveals a slight increase up until the last measurement at 180 minutes. 
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Figure 30: Flow cytometry investigation of exponentially growing E.coli exposed to peptides at concentrations 
corresponding to 1x and 4xMIC. Lightscatter is equivalent to cell size, fluorescence corresponds to cellular DNA 
content and  fluorescence/lightscatter ratio is a measure of the DNA content depending of cell size. The experiment 
was performed over the course of 3 hours in a microtitter plate format with an inoculum of OD600 of 0,1 and 
incubated at 37°C between sample extractions. Whenever possible, 20.000 events were included in the analysis.  
 
Investigations of the peptides effect on bacterial DNA content, intriguingly revealed that the 
addition of GN-2 at 4xMIC following an initial decrease in fluorescence, increases after 40 
minutes and end up displaying a larger content of DNA than the control samples [Fig. 30]. On 
the other hand, GN-2 at MIC induces a similar initial decrease in DNA that persists over the 
course of 3 hours. Contrary, no clear difference between the effect of adding 4xMIC and 1xMIC 
concentration of GN-6, with both concentrations inducing a similar persistent decrease [Fig. 30]. 
The decrease in DNA observed for both peptides might reflect actual inhibition of DNA 
machinery or more likely indirect inhibition e.g. due to membrane disturbances, although no 
definite answer is provided by this assay.   
The ratio between fluorescence and lightscatter, which translates into the ratio between DNA 
content and cell size, is interdependent correlated in a healthy bacterial population and 
investigation of this parameter, therefore enables a more complete indication of the effect of the 
peptides on E.coli. The control sample has a fairly constant ratio of DNA in relation cell size, as 
expected in a normal growing bacterial population. At concentrations corresponding to MIC for 
both peptides, a rapid decrease in the ratio of DNA in relation to cell size is observed up until 40 
minutes, followed by an increase towards the level of the control [Fig. 30]. Of note, is the 
increase in DNA in relation to cell size most pronounced for the GN-2 sample. Both peptide 
samples at MIC, display a ratio between DNA and cell size after 120 minutes, similar to the 
GN-2, 1xMIC, 180 
min 0 min 
Control, 0 min Control, 180 min GN-2, 4xMIC, 180 
min 0 min 
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control, which could indicate a process of recovery at this time. For the GN-6 samples, exposure 
to 4xMIC induce a rapid and persistent decrease in the ratio between DNA and cell size, equally 
contributed by a steep increase in cell size and a likewise steep decrease in the DNA content. In 
the case of GN-2 at 4xMIC, a slight increase is observed after 40 minutes, which primarily should 
be ascribed to the reestablishment of DNA content which occurs at this time.   
 
In hope of identifying potential bacterial targets of the peptides, bacteria exposed to ampicillin 
and ciprofloxacin, acting on the cell wall and DNA machinery respectively, was included to 
compare the effect on bacteria [Fig. 31]. Ampicillin induces a continuous increase in cell size and 
DNA content at a concentration corresponding to 2x MIC [Fig. 31], likely because of the cells not 
being able to divide, similar to (Walberg et al., 1997, B). It should be noted that it was not 
possible to obtain reliable data at 180 minutes for 8 µg/ml of ampicillin due to large amounts of 
cell debris which made it impossible to identify a bacterial population in the collected sample. 
  
The DNA gyrase inhibitor ciprofloxacin, causes a substantial increase in cell size, most 
pronounced at the highest concentration [Fig. 31], consistent with previous results from 
(Walberg et al., 1997, B) and observations about filamentation of cells following quinolone 
treatment (Drlica et al., 2008). The higher concentration of ciprofloxacin likely results in a more 
pronounced growth inhibition and higher degree of cell degradation which can explain this 
phenomenon.  When comparing the ratio between DNA content to cell size it becomes apparent 
that both concentrations of ciprofloxacin induces a substantial decrease which can be attributed 
to the increase in cell size while retaining a somewhat constant DNA content.  
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Given the fact that both ampicillin and ciprofloxacin, with the cell wall and DNA machinery as 
their targets, induce a similar increase in bacterial size at higher concentrations, it is not 
possible to extrapolate the increased cell size observed in peptide treated samples, explicitly to 
either of these targets. Also, the main difference when comparing the effect of ampicillin and 
ciprofloxacin to the effect of peptides is the rapid change in both cell size and DNA content 
exerted by peptides, whereas both antibiotics have an effect that manifests gradually. 
Accordingly, it is conceivable to think that the peptides exert their antibacterial effect 
fundamentally different from ampicillin and ciprofloxacin.  
In summary the results obtained from the flow cytometry investigation, reveals a remarkable 
and unrelenting increase in E.coli size, together with a steep decrease in DNA content after 
exposure to bacteria with GN-2 and GN-6 at 4xMIC. Lower concentrations seemingly did not 
affect cell size noteworthy but had a similar effect as higher concentrations on the DNA content. 
The precise mechanism behind these observations is yet to be discovered. 
 
Figure 31: Flow cytometry investigation of exponentially growing E.coli exposed to Ampicillin and Ciprofloxacin at 
concentrations corresponding to 1x and 4xMIC. Lightscatter is equivalent to cell size, fluorescence corresponds to 
cellular DNA content and  fluroescense/lightscatter ratio is a measure of the DNA content depending of cell size. The 
experiment was performed over the course of 3 hours in a microtitter plate format with an inoculum of OD600 of 0,1 
and incubated at 37°C between sample extractions. When possible 20.000 events were included in the analysis. 
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To support the results about morphology obtained from the flow cytometry samples, phase 
contrast pictures of the flow samples were taken, [Fig. 32]. The microscopy investigation of the 
control samples, support the 
result of decreasing cell size over 
time, which was observed in the 
lightscatter measurements in the 
flow cytometry. No distinct 
morphologic changes are visible 
for both peptides at MIC, when 
compared with the control 
samples, although there is a 
slight indication towards the 
bacteria in the GN-2 treated 
samples are bigger than what is 
observed in the control and the 
GN-6 treated samples. The 
samples treated with GN-2 at 
4xMIC show signs of cell lysis, as 
large areas of cell debris are 
present, together with cells that 
appear to have lost their cellular 
content by judging from their 
transparent appearance. Also, 
the cells appear to be of a size that is considerably larger than the control samples. The bacteria 
exposed to GN-6 at 4xMIC show clear-cut changes in their morphology by being long and 
filamentous but no apparent lytic effect is observed. In general, the observed morphology 
followed by peptide exposure is in agreement with the results obtained from the flow cytometry 
assay. 
  
Figure 32: Microscope pictures of E.coli ethanol stained flow cytometry 
samples with indications of bacteria that appear to lost their cellular 
content due to their transparent look. Pictures are taken with an 
automated Leica DM5000 B microscope (phase contrast) 100x 
magnification. 
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MEMBRANE INTERACTIONS 
VISUALIZATION OF MEMBRANE PERMEABILIZATION  
The live-dead staining kit was applied to peptide treated E.coli, to visually investigate the 
membrane permeability capabilities of the peptides. The assay makes use of the SYTO9 green-
fluorescent nucleic acid stain together with the red-fluorescent Propidium Iodide stain and their 
different capacity to penetrate bacterial membranes. When SYTO9 is used alone, it will stain 
both live and dead bacteria independent of membrane integrity. Propidium Iodide will only 
penetrate damaged membrane and thereby suppress the green fluorescence mediated by 
SYTO9 of cells with damaged membranes. This allows for the combinatory use of these 
fluorescent dyes to distinguish between live cells, with intact membranes which will appear 
green, and cells with damaged membranes will be scored as dead and fluoresce red. To follow 
the changes of membrane integrity over time, microscopy pictures are taken at the indicated 
time point, with the control samples in the top panel, bacteria exposed to GN-2 at MIC in the 
middle panel and finally bacteria exposed to GN-2 at 4xMIC at the bottom panel, [Fig. 33].  
  
 
 
From microscope investigation of the extracted samples, it was clear the control samples 
displayed almost exclusively green fluorescence throughout the assay of 2 hours, verifying that 
Untreated 
controls 
GN-2, 4xMIC 
Figure 33: Live dead visualization of  E.coli ATCC 25922 over the course of 2 hours.  Untreated controls (Top panel) and 
exposed to GN-2 at 1xMIC (Middle panel) and 4xMIC (Bottom panel) at the indicated intervals. Pictures are taken with a 
Leica DM5000B microscope using a mercury lamp. A filter cube with excitation filters of 436, 495 and 580 nm and 
emission filters of 460, 535 and 630 nm was used to be able to detect both live and dead bacteria.    
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control samples essentially have intact membranes under the conditions applied in this assay. 
Interestingly, bacteria challenged with GN-2 at MIC, showed that around 80-90 % of bacteria 
fluoresced red, after 10 minutes and investigation after 20 minutes gave fundamentally the 
same pattern. From 40 minutes to the last time point at 120, it would seem that there is a 
gradual recovery in membrane integrity, ending up with essentially only bacteria with intact 
membranes at 120 minutes. In the case of GN-2 at 4xMIC, it is possible to deduce a rather 
unambiguous development over the course of 120 minutes with all observations displaying 
fundamentally only bacterial cell with loss of membrane integrity. The assay was also conducted 
with GN-6, showing the same trend and was therefore omitted for clarity. Although this assay 
gives clear indications to the peptides inducing membrane permeabilization, it suffers from only 
being able to investigate very small samples of the bacterial population which is why a more 
quantitative approach was assigned next. 
QUANTIFICATION OF MEMBRANE PERMEABILIZATION 
The quantitative approach to determine membrane permeabilization makes use of the two 
previously described nucleic acid stains, SYTO9 and Propidium Iodide, which allows for the 
detection of live and dead bacteria, based on their membrane integrity. The assay was 
conducted in a 96-well format with a starting bacterial inoculum of OD600 0,1 with peptide 
concentrations corresponding to 1x, 2x and 4x MIC concentrations. 
 
 
  
Figure 34: Live dead quantification based on the ratio of red fluorescence (dead bacteria) and green fluorescence (live 
bacteria). Percent of live bacteria after treatment with 1x, 2x and 4xMIC concentrations of peptides GN-2 and GN-6. 
100% are set as the value from untreated samples at time 0. Results are 3 independent experiments. Error bars 
designate SEM. The experiment was done in a 96-well format and the plate was Incubated at 37°C between 
measurements. 
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Interestingly, addition of both peptides corresponding to MIC induced a similar reduction in live 
bacteria down to around 20 % at 10 minutes, demonstrating a rapid membrane permeabilizing 
effect of both peptides [Fig. 34]. In the case of peptide addition at MIC, a steady increase in the 
proportion of live bacteria after 10 minutes in the case of GN-2 and after 40 minutes for GN-6 is 
observed. This could be related to bacteria that are able to recover from the initial membrane 
permeabilization or growth of a surviving population of bacteria. At peptide concentrations 
corresponding 2x and 4x MIC the initial level of inhibition already after 10 minutes is 
maintained over the course of 120 minutes, indicating that the peptides induce unrecoverable 
membrane permeabilization in the far majority of the bacterial population.   
No immediate explanation to the slightly elevated proportion of live cells at 50 µg/ml compared 
to 25 µg/ml for GN-6  can be provided. Based on previous observations, the patch of 4 
consecutive Trp residues was suspected to have auto fluorescence characteristics (Fleming et 
al., 1978) that could explain the increased fluorescence but experiments with both amino acids 
gave only negligible fluorescence readings (data not shown) which could not explain the 
observed results.  
LPS INTERACTION 
LPS are thought to be one of the first components of gram-negative bacteria to interact with 
AMPs and is the major cause of sepsis in relation to gram-negative infections and has previously 
been shown to interact with various AMPs (Rosenfeld & Shai, 2006). In that perspective, the 
ability of GN-2 and GN-4 to bind LPS isolated from P.aeruginosa PA01 was investigated by using 
isothermal titration calorimetry (ITC). The reason for choosing GN-4 instead of GN-6 relates to 
the availability of the peptide because the assay required relatively large quantities in 
comparison with other assays. A more thorough explanation of the concept of ITC is given in the 
experimental section but in short, heat is either produced or absorbed when two molecules bind 
and this change is registered by the ITC device, ideally allowing the determination of 
thermodynamic parameters such as enthalpy, entropy, and free energy associated with binding. 
In this case, the diversity of LPS required assumptions to be made about the molecular weight of 
LPS (10kDa). In alignment with a previous publication (Bhunia et al., 2007), detailed 
determination of thermodynamic binding parameters were therefore not conducted. The initial 
challenge with peptide was performed by titrating 1,38 mM of GN-4 peptide into 0,1 mM of LPS. 
This produced a thermogram [Fig. 35A] with a downward trend in the titration peaks, indicating 
an exothermic binding process. The increase in magnitude of the titration peaks, which can be 
seen after 120 minutes, is the result of increasing the injection volume from 2 µl to 4 µl in hope 
of reaching saturation. From integration of the titration peaks, it is possible to obtain the change 
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in enthalpy, displayed below the titration peaks. In an attempt to reach saturated binding, the 
concentration of LPS was decreased to 0,05 mM and GN-4 was added at 1mM, revealing a 
somewhat similar thermogram with downward peaks and titration curve showing negative 
changes in enthalpy [Fig. 35B]. The decreased concentration of LPS, made it possible to see 
signs of saturation with the titration peaks approaching the baseline, at a molar ratio of peptide 
to LPS of 3. Additionally, if the first two peaks and the corresponding enthalpy points of the first 
GN-4 sample [Fig. 35A], are ignored, it would seem that the two GN-4 samples show similar 
characteristics with a slow decline in enthalpy. To elaborate on the binding characteristics of 
the peptides against LPS, it was attempted to apply the assay for the GN-2 peptide, revealing 
roughly the same binding features [Fig. 35C]. To compare the binding of the peptides with a 
known LPS binding substance, Polymyxin B was used [Fig. 35D]. Polymyxin B is considered the 
golden standard of LPS binding (Mares et al., 2009) and should therefore give a thermogram 
corresponding to strong LPS binding. Interestingly, the application of Polymyxin B revealed a 
rather different thermogram than the ones obtained with peptides, with an upwards trend of 
peaks and a positive enthalpy change, previously assigned to a more complex interaction with 
LPS extending beyond electrostatic interactions (Brandenburg et al., 2005). The thermograms 
obtained with peptides were not entirely conclusive but when the results from Polymyxin B  are 
taken into account, the reliability of the assay is strengthened because the thermogram of 
Polymyxin B is very similar to what has previously been published (Brandenburg et al., 2005). 
Previous ITC results in different settings have concluded that binding, relying solely on 
electrostatic attraction, give rise to exothermic reactions (Carneiro et al., 2002), thereby making 
it plausible to assign the binding of the peptides with LPS, primarily to electrostatic interactions.  
When reviewing the results, the assay is not entirely conclusive, suffering from low 
reproducibility but there are indications of LPS binding of both GN-2 and GN-4 although the 
affinity is considerably lower than Polymyxin B, by judging from the enthalpy values.   
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Figure 35: Thermographs of GN-4 (A and B), GN-2 (C) and Polymyxin B (D) titrated into LPS. (A): 1,38 mM GN-4 titrated 
into 0,1 mM LPS at 20°C. The increase observed after 120 min in the thermogram is the result of increasing the injection 
volume from 2 µl to 4 µl in an attempt to reach saturation. (B): 1 mM GN-4 titrated into 0,05 mM LPS at 20°C. (C): 1 mM 
GN-2 titrated into 0,05 mM LPS at 20°C. (D) 1 mM Polymyxin B titrated intro 0,1 mM LPS at 20°C. 
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LEAKAGE FROM OF MODEL MEMBRANES 
Previous assays suggested that the peptides exerted membrane disruption. In order to verify 
this hypothesis, unilamellar phospholipid vesicles (LUVs) made of POPG:POPC in a 7:3 molar 
ratio as a simple mimic of bacterial membrane (Jahnsen et al., 2012), were prepared with 
entrapped calcein. This would allow the release of calcein – indicative of membrane leakage to 
be measured. LUVs are a widely accepted model for studying membrane interactions, especially 
in bacteria since the size of 0,1 µm is close to that of bacteria (Zhang et al., 2010). Calcein is 
entrapped in LUVs at self- quenching concentrations, giving a relatively low background and 
fluorescence is therefore mainly detected when calcein is released from LUVs, resulting in 
dilution of calcein, thereby enabling more pronounced fluorescence to occur (Benachir & 
Lafleur, 1995).  
 
All of the peptides were able to induce concentration dependent calcein release of the liposomes 
to various degrees. When comparing the release induced by peptides after 5 min, [Fig. 36], it is 
apparent that the peptides with the greatest antibacterial activity, GN-2 to GN-6, are also the 
Figure 36: : Calcein release from 20µM POPG:POPC, 7:3 molar ratio vesicles at 37°C. 100 % leakage was set as the release 
after addition of 10% Triton X-100 and all readings were baseline corrected by substracting values from liposomes 
without addition of peptides. Depicted results are the mean of three independent experiments with good 
reproducibility. Error bars are omitted for clarity.  
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ones displaying the greatest degree of calcein release. Though, within the most active peptides 
there is considerate variation, with GN-2 inducing 100 % leakage at a concentration of 5,6 
µg/ml whereas GN-5 only induce 60 % release at this concentration after 5 minutes [Fig. 36]. 
Interestingly, the difference in leakage of between the most active peptides is substantially 
diminished after 60 minutes making it virtually impossible to visually differentiate between 
their ability to induce leakage. This suggests that variation in the capability to induce calcein 
release within this group of peptides should primarily be ascribed to the kinetics of release, 
rather than the endpoint release after 60 minutes. The same pattern can be attributed to the 
group of less active peptides, GN-8 to GN-14, although their ability to cause calcein release, in 
general was slightly lower. Worth noting is the small difference in concentration between minor 
and complete release, with concentrations around 2 µg/ml for the most part only inducing 
minor release and a concentration around 7 µg/ml inducing complete release for the most 
active peptides after 60 minutes. This suggest a very defined ratio of peptide to LUVs, required 
for inducing membrane permeabilization for the most active peptides, which was verified by 
observing calcein release over time, [Fig. 37].  
 
GN-2 evidently induce liposome leakage instantly, with no significant increase of leakage during 
the assay and within a very narrow concentration spectrum of 5,5 to 1,7 µg/ml inducing 100- 
and 5% release, respectively [Fig. 37]. GN-4 displays a similar instant release pattern, although 
Figure 37: Calcein release from 20 µM POPG:POPC, 7:3 molar ratio vesicles at 37°C following peptide exposure over the 
course of 1 hour. 100 % leakage was set as the release after addition of 10% Triton X-100 and all readings were baseline 
corrected by substracting values from liposomes without addition of peptides. Depicted results are the mean of three 
independent experiments with good reproducibility. Error bars are omitted for clarity 
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Figure 38: Calcein release from 20 µM 
POPG:POPC, 7:3 molar ratio vesicles at 37°C 
following Melittin exposure over the course 
of 1 hour. 100 % leakage was set as the 
release after addition of 10% Triton X-100 
and all readings were baseline corrected by 
substracting values from liposomes without 
addition of peptides. Depicted results are 
the mean of three independent 
experiments with good reproducibility. 
 
the potency appears to be slightly lower than GN-2 peptide. GN-6, which is slightly less potent 
against bacteria, exerts a more gradual release of calcein over time and has a more gradual 
release over a wider concentration spectrum, suggesting a different mode of liposome leakage 
for this peptide. Review of the release over 60 minutes, for GN-8, GN-12 and GN-14 reveal a 
more distinct gradual release which progresses with increasing release up until about 20 
minutes. Hence, the most active peptides against bacteria can be summarized to exert calcein 
release almost instantly whereas the less active peptides exert a gradual release of calcein from 
liposomes. Calcein release of the rest of the peptides from the GN-library can be found in 
Appendix I. 
The peptide Melittin, isolated from bee venom, was 
included as a positive control for liposome disruption 
as it is a well-known non-selective lytic peptide (Shai, 
2002). As expected, Melittin show superior capability 
in mediating calcein release [Fig 38], with release of 
roughly 50% at the rather low concentration of 0,9 
µg/ml similar to previous leakage experiments with 
Melittin (Hadjicharalambous et al., 2008). 
Interestingly, Melittin, although at lower 
concentrations, evidently induce a similar instant 
release of calcein as the most active peptides, 
suggesting a similar mechanism of mediating release 
from liposomes.  
In summary, this assay clearly demonstrates all of the 
peptides ability to induce substantial calcein leakage 
from LUVs of POPG:POPG at concentrations relevant 
for bacterial inhibition. The assay show great 
correlation in the ability to induce calcein leakage 
from liposomes and antibacterial activity evaluated 
by MIC testing.  
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DETERMINATION OF SECONDARY STRUCTURE IN MEMBRANE MODELS 
Secondary structure has in many contexts been shown to be important for activity of AMPs and 
consequently, secondary structure was investigated using CD spectroscopy. Secondary 
structure of this library of peptides was investigated, both in Tris buffer pH 7,4, and LUVs 
consisting of POPC:POPG:Cholesterol (5:3:2 molar ratio) and POPG:POPC (7:3 molar ratio), 
mimicking mammalian and bacterial membranes, respectively [Fig. 39].  
As expected, all peptides gave CD spectra in Tris buffer, bearing little resemblance with any 
well-defined secondary structure, indicating a random structure under these conditions. The 
GN-5 peptide showed the greatest fluctuation from the baseline, which might be because of it its 
patch of 5 consecutive Trp residues. In the presence of mammalian mimicking LUVs, the lytic 
peptide Melittin adapted a spectra characteristic of α-helical content with negative bands at 222 
and 208 nm (Greenfield, 2007). This was supported by the use of the K2D algorithm 
(www.dichroweb.cryst.bbk.ac.uk), which based on CD spectra can predict the percentage of 
secondary structure, predicting an α-helical content of Melittin of 77% [Table 4], which is in 
agreement with previous publications (Wessman, et al 2008; Brogden et al., 2005; Bechinger et 
al., 1997). In comparison, the only two GN-peptides that produced CD spectra enabling the K2D 
algorithm to calculate secondary structure was GN-9 and GN-11, both having an α-helical 
content of 8% and β-sheet content of 30%, demonstrating that these peptides primarily adapt 
random structures in the presence of mammalian mimicking LUVs. The CD spectra from both 
bacterial and mammalian mimicking LUVs are very similar, showing the same degree of α-
helical content of the non-cell-selective Melittin, and essentially the same spectra for the GN-
peptides. It should be noted though, that GN-5, GN-6 and especially GN-12 give a distinct 
Figure 39: CD spectra of peptides in Tris pH 7,4, POPC:POPG:Cholesterol (5:3:2 molar ratio) and POPG:POPC (7:3 molar 
ratio) LUVs.  Peptide concentration was 20 µM and LUV concentration 2mM to obtain a lipid-peptide ratio of 
100:1.Spectra from 240 nm to 250 nm were omitted since no peptides deviated significantly from the baseline in this 
range. Readings below 200 nm were excluded because the photomultiplier tube (PMT) voltage exceeded 700 V making 
the data unreliable. Results are the mean of 5 scans and are smoothed using the Savitsky-Golay algorithm. 
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α-helical content of the peptides where the error limits allowed calculation with K2D algorithm in the presence of Tris, 
mammalian and bacterial mimicking LUVs. N.D. denotes not detectable because of large error margins. 
 
negative band around 228 nm in both LUV suspensions but it was not possible to ascribe this to 
any specific structure.  
TABLE 4: α-helical content of peptides 
 
 
The K2D algorithm was able to calculate secondary structure for a greater proportion of the GN-
peptides in bacterial mimicking LUVs [Table 4], most prominently predicting an α-helical 
content of 26 % of the GN-4 peptide. It should be noted, that although the presented structural 
predictions based on K2D are within the error limits of the algorithm, the error margins were 
quite high, suggesting caution in concluding on these numbers.  
This assay was not able to convincingly detect any dominant structure of the GN-peptides in any 
of the conditions tested and based on this assay it must be assumed that the GN-peptides exert 
both their antibacterial and cytotoxic activity without adapting any well-defined secondary 
structure.  
  
  Tris  Mammalian LUVs Bacterial LUVs 
Melittin 27 % 77 % 78 % 
GN-4 N.D. N.D. 26 % 
GN-8 N.D. N.D. 10 % 
GN-9 N.D. 8 % 10 % 
GN-11 N.D. 8 % N.D. 
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DISCUSSION 
Inspired by the compiling problems related to bacterial resistance against conventional 
antibiotics, this work focuses on a group of compounds that has the potential to act as lead 
structures for future development of antibiotics, namely AMPs. The widely accepted potential of 
AMPs is tailored around their multifaceted antibacterial activity, together with their immune 
modulation capabilities (Fjell et al., 2012), although the last mentioned feature is not within the 
scope of this thesis. Despite the identification of more than 1000 natural AMPs, a detailed 
understanding of the mechanism by which these peptides induce bacterial inhibition, is only 
known for a small fraction these, thereby obstructing the possibility to unravel their potential as 
antibacterials. Consequently, this thesis focuses on characterizing the mechanism behind the 
antibacterial effect of a small library of AMPs. 
SELECTIVE ACTIVITY 
Antibacterial activity was determined for both the Bac and GN-library against E.coli, S.aureus 
and P.aeruginosa but for this activity to have therapeutic relevance, the peptides would have to 
exert sufficient selectivity towards bacterial membranes to limit potential toxic effects. Thus, the 
following section will assess and compare both the antibacterial and toxic activity of the 
peptides. 
 
Attempts to design improved variants of Bac8c by various amino acid substitutions failed to 
produce peptides with comparable broad spectrum activity but were at the same time 
practically non-toxic against RBCs. This feature could prompt for using the Bac-3 peptide, which 
shows a therapeutic index (TI) of 80 against E.coli [Table 3], as a lead structure for development 
of selective peptides with superior potency in the future.  
In contrast to the Bac-library, the investigation of the antibacterial activity of the GN-library 
revealed rather potent and broad spectrum activity of most of the peptides. In that perspective 
it is interesting to note that all of the most active peptides have Arg or Lys and in some cases 
also Trp, in various order, as their first three residues [Table 3]. This could indicate that cationic 
and bulky amino acids in the amino-terminal part of the sequence are beneficial for 
antibacterial activity, at least within this library of peptides. In relation, the role of Arg and Lys 
have previously been highlighted as mediators of clustering anionic lipids, leading to membrane 
instability, in gram-negative bacteria models (Wadhwani et al., 2012) and a similar mechanism 
might explain their antibacterial promoting effect in this part of the sequence. Contrary, all of 
the peptide which are less active against P.aeruginosa and S.aureus  (GN-8, GN-9, GN-11 and GN-
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14) have either Ile or Leu as a part of the first three residues [Table 3], which could be related to 
these peptides originating from the part of the GN-library that was predicted to be less active 
(Fjell et al., 2011). The role of Trp, Lys and especially Arg in mediating antibacterial activity, has 
previously been highlighted (Chan et al., 2006) and the observed pattern in activity related to 
the sequence, might be a mixture of the potency of these residues and their position in the 
sequence, in accordance with previous observations (Cherkasov et al., 2009).  Despite the fact 
that allocation of certain amino acids in specific parts in the sequence within this library seem 
to affect activity, the great diversity of AMPs and complex structure activity relationships, 
probably limits the application of these findings to peptides with similar length and charge. 
In addition to displaying potent activity against bacteria, various degrees of hemolysis and 
toxicity towards Hela cells was observed for the GN-peptides. The rather unambiguous 
correlation between bacterial potency and cytotoxicity displayed by most GN-peptides [Table 3] 
makes it conceivable to think that the traits that confer effective bacterial activity are the same 
that account for toxic effects. In support of this, Bac8c, previously identified as membrane active 
(Spindler et al., 2011), displayed a similar correlation between antibacterial and hemolytic 
activity in this study [Table 2], implying that these activities are somehow correlated for 
membrane acting antimicrobial peptides of this size. In an attempt to identify peptide traits that 
could explain hemolytic activity, the correlation with hydrophobicity, which is generally 
accepted to be a major determinant for hemolytic activity of AMPs (Melo et al., 2009) was done, 
revealing no distinct association, implying that the sum of different factors are responsible for 
the hemolytic activity. The most hemolytic peptides were GN-2 and GN-4 [Fig. 23], which also 
displayed the greatest broad spectrum potency against bacteria. Interestingly, they have the 
same charge distribution along their primary structure, differing only in the substitution of Arg 
for Lys (position 4) and Ile for Leu (position 9) [Table 3], suggesting this charge distribution as 
the most potent composition for both desirable and undesirable membrane interactions. Lys 
residues has previously been ascribed to a greater lytic effect of AMPs compared to Arg 
(Wadhwani et al., 2012) and accordingly GN-4, with Lys instead of Arg, was more hemolytic 
than GN-2.   
 
The toxic contribution of the peptides against mammalian cells was evaluated further by the 
MTT assay uncovering a disproportional high toxicity compared to hemolysis assay [Table 3]. 
This could be related to the peptides exerting cancer cell selectivity due to the high content of 
anionic phospholipids of these cells, similar to previous observations (Slaninova et al., 2012). 
Another explanation might be that the peptides after entering the Hela cells selectively target 
the mitochondrial membrane, due to its bacterial resemblance, similar to previous observations 
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(Eliassen, 2006). This would likely result in an inhibition of metabolism that is disproportional 
to the membrane disruptive effect of the cytoplasmic membrane and the assay might not be an 
accurate measure for the peptides propensity to damage eukaryotic membranes. Nevertheless, 
disruption of the mitochondrial membrane will likely be lethal to eukaryotic cells and the 
selective activity will therefore need further improvement for future employment of these 
peptides.  Regardless of the possible explanations for the substantial toxicity exerted by GN-2 
and especially GN-4 against Hela cells, the observed toxicity is a cause for concern and needs 
further characterization e.g. by conducting toxicity studies on non-cancerous mammalian cells 
or by employing the peptides in animal studies, to reveal the true extent of mammalian toxicity 
of these peptides.  
SYNERGY WITH ANTIBIOTICS 
The possible effect of AMPs reconstituting the effectiveness of conventional antibiotics, when 
applied together, has been suggested to constitute the greatest therapeutic potential of AMPs 
(Giacometti et al., 2005) and accordingly this possibility was investigated.  The synergistic effect 
of both GN-2 and GN-6, when applied together with the cell-wall acting agent ampicillin against 
S.aureus, could be related to increased access of peptides to the cytoplasmic membrane. More 
specifically, the cross-linking of peptidoglycan strands, which ampicillin inhibits, takes place 
outside the cytoplasmic membrane (Fisher, 2005) and ampicillin could therefore be 
hypothesized to indirectly inflict gradual degradation of the peptidoglycan layer by not 
counteracting the degradation by autolysins. The disintegration of the peptidoglycan would 
make the cytoplasmic membrane more accessible to the peptides which could lower the 
concentration needed for the peptides to exert their activity.  Conversely, the additive effect 
which is observed for GN-2 and GN-6 together with ampicillin against E.coli could be related to 
the peptides inducing increased permeability of the outer membrane to allow a greater access 
of ampicillin to the peptidoglycan layer, although this is purely hypothetical. The additive effect 
observed between ciprofloxacin and the peptides could be related to the peptides inducing 
increased permeability in the bacterial membrane, thereby easing ciprofloxacin uptake.  
Regardless of the exact mechanism, the observed synergy and additive effect has a substantial 
therapeutic potential by potentiating conventional antibiotics, thereby minimizing risk of 
resistance and the development of adverse effects in treatment. It should be noted though, that 
the reliability of the checkerboard assay has previously been questioned in assessing the 
cooperative effects of antibacterials (Wootton et al., 1995) and the obtained FIC values should 
therefore only serve as indications of potential cooperative effects.  
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KILLING KINETICS AND MORPHOLOGY 
When evaluating the kinetic and morphology assays it is important to keep in mind that the 
assays were performed with a starting inoculum of OD600 of 0,1, roughly equivalent to 107 
cfu/ml which is almost 100 times higher than what was used in the MIC assay. The starting 
inoculum is of critical importance for the determination of MIC and increasing the bacterial 
numbers will almost certainly increase the MIC values (Wiegand et al., 2008). With than in mind 
the kinetic and morphology assays are in many respects conducted at sub-MIC exposure. 
However, for the sake of nomenclature consistency, MIC will refer to the concentrations of 
peptides that inhibit bacterial growth under the conditions applied in the MIC assay. 
EFFECT AT MIC EXPOSURE 
From both flow cytometry and viability assays, it was apparent that both GN-2 and GN-6 had an 
effect on bacteria that manifested rather quickly, [Fig. 25 & 30]. Exposure to both peptides at 
MIC induces a period of 80 minutes with a constant number of CFU, before an increase towards 
the level of the control samples is observed. This could be explained by this level of peptide 
exposure inducing a metabolic disturbance that halts bacterial growth in this period, before 
growth is reestablished. The hypothesis of the peptides affecting metabolism at MIC is 
supported by the OD measurements, which revealed a decreased growth rate under similar 
conditions. It should be noted though, that the OD readings revealed a steady increase over the 
course of 4 hours, with no plateau like the one observed in the viability assay [Fig. 25 & 26]. 
Hypothetically, this could be related to the cells having continued protein synthesis, translating 
into an increased OD, but at the same time not being able to divide. Intriguingly, the flow 
cytometry analysis revealed a period of 80 minutes with somewhat steady cell size at MIC 
exposure of peptides [Fig. 30],  supporting the idea that the bacteria are caught in some kind of 
reversible metabolic standstill, before returning to what would appear to be nor mal growth. In 
support of this, the microscope investigation of the bacteria revealed no obvious morphologic 
difference between the MIC exposed bacteria and the control, although a slight indication of the 
MIC treated cells were bigger [Fig. 32]. A slight increased cell size in the MIC exposed bacteria, 
also seen in the flow cytometry analysis, could be explained by a metabolic inhibition that 
results in delayed onset of the decrease in cell size which normally sets in when the bacterial 
suspension gets denser (Steen, 2000). In conjunction, the findings rather unambiguously 
suggest that when a starting inoculum of roughly 107 cfu/ml is exposed to peptides at MIC, some 
kind of reversible metabolic inhibition takes place, from which the bacteria apparently recovers. 
Despite the differences in OD measurements and visual inspection of morphology, the difference 
between GN-2 and GN-6 is not sufficiently distinct to allow confident differentiation of their 
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mechanism of action because the flow cytometry analysis and CFU counts are virtually 
indistinguishable.  
EFFECT ABOVE MIC EXPOSURE 
At 4xMIC exposure of both peptides, viability of E.coli was reduced a 1000-fold after 40 minutes, 
indicating a somewhat rapid bactericidal inhibition. This could be explained by the peptides 
inducing bacterial lysis, visually verified for the GN-2 after 180 minutes. Contrary, GN-6 
displayed clear signs of filamentation of bacteria with no visual signs of lysis. In support of the 
peptides inducing bacterial lysis at higher concentrations is the decrease in OD, previously 
ascribed to lysis (Pasotti et al, 2011) observed at 2xMIC exposure. When considering the flow 
cytometry samples that showed an indistinguishable increase in cell size, already at the first 
measurement at 20 minutes for both of the peptides, it is conceivable to think that both peptides 
induce filamentation, since an increase in lightscatter has previously been ascribed to 
filamentation following antibiotic treatment (Walberg et al., 1997, A). The results obtained in 
the flow cytometry analysis should also carry more weight as it relies on the analysis of 20.000 
bacteria whereas only a tiny proportion is analyzed in the microscope investigation, supporting 
the development of filamentous bacteria after exposure to GN-2 and GN-6. The mechanisms 
behind filamentation, has previously been ascribed to induction of SOS response, both following 
ciprofloxacin and β-lactams (Kohanski et al 2010), and since the SOS response can be induced 
by multiple environmental stresses (Galhardo et al., 2007), the observed filamentation cannot 
be ascribed to the peptides targeting specific bacterial components.  
 
The general trend in the kinetic and morphology assays is that there is a concentration 
dependent inhibition although higher concentrations than MIC are generally required for 
bacterial inhibition, likely related to the rather high inoculum of bacteria. This could attenuate 
the actions of the peptides, especially if the peptides act by membrane disruption since this 
mechanism has been related to the peptides reaching a critical concentration of the surface of 
the bacteria before inhibitory membrane interactions takes effect (Huang, 2006). Furthermore, 
most of these assays required the use of polystyrene plates, previously tailored to lower 
potency of peptides because of the negative charge of the plastic material, suggestively 
mediating unselective binding of the positively charged peptides (Wu & Hancock, 1999; 
Wiegand et al., 2008). The precise effect of using polystyrene plates is although a matter of 
debate (Sanchez-Gomez et al., 2008) and the effect, likely depends on both peptide and bacterial 
characteristics. Though, preliminary data could indicate a weakening effect of the GN-peptide 
activity in polystyrene plates (data not shown) although the data were not entirely conclusive.   
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LUMINESCENCE SCREENING 
The use of luminescent P.aeruginosa to evaluate the effectiveness of peptides, was primary 
applied for future screening purposes but it also revealed some valuable parameters for the 
activity of GN-2. Serum concentrations of NaCl seemingly induced a mildly dampening effect on 
GN-2 ability to inhibit P.aeruginosa metabolism, whereas both Ca2+ and Mg2+ increased the 
inhibitory concentration more profoundly with 2-3 fold compared to Tris. Although the 
mechanism of antagonistic effect of both salts and divalent cations are not uncommon (Jenssen 
et al., 2006; Friedrich et al., 1999), it is a feature that has to be taken into account when 
assessing the therapeutic potential of GN-2. The rationale between divalent cation inhibition of 
peptide activity in this setting, might be related to the fact that LPS, which is thought to be the 
first and single most important encounter with peptides in gram-negative, bacteria are 
stabilized by Ca2+ and Mg2+ (Kotra et al., 1999; Zasloff, 2002). Consequently, it seems conceivable 
to think that increasing concentrations of cations would attenuate AMP ability to displace 
cations from the negatively charged entities of LPS, thereby hampering possible membrane 
interactions of AMPs. The inhibition of P.aeruginosa in the luminescense assay does not reveal if 
the peptide induce metabolic inhibition by constraining the metabolic machinery or if the 
decrease in luminescence is brought about by other mechanisms such as a drop in ATP levels 
following membrane leakage, as previously suggested (Hilpert et al., 2005). Adittionally, direct 
interaction of other AMPs with ATP has previously been reported (Hilpert et al., 2010) and this 
possibility cannot be excluded but based on the findings from other assays it seems more likely 
that GN-2 induce some degree of membrane disturbance at higher concentrations which 
indirectly affects intracellular ATP levels.  
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MEMBRANE INTERACTIONS 
EFFECT AT MIC EXPOSURE 
The visual inspection of bacterial membrane permeability revealed that membrane integrity 
was compromised at MIC challenge of bacteria with both GN-2 and GN-6 after 10 minutes [Fig. 
33], followed by a gradual re-establishment of membrane integrity, also seen in the quantitative 
assay [Fig. 34]. Interestingly, this phenomenon seem to take place somewhere between 40 and 
80 minutes, suggesting a possible correlation with the observations of constant cell size from 
flow cytometry analysis and standstill in CFU, observed roughly in the same timeframe. Using 
the same LIVE/DEAD BacLight kit, the mechanism behind the apparent gradual recovery of 
membrane integrity has previously been assigned to resealing of the membrane leading to 
Propidium Iodide (PI) exclusion (Mousaa et al., 2007), although it was after decompression and 
not exposure to antibacterials. Also, some strains of bacteria have been suggested to have efflux 
pumps that drive PI out of the cell (Stocks et al., 2004). Such a process would require some 
degree of metabolism to provide ATP for efflux pumps and the putatively exclusion of PI. In that 
perspective, it has previously been suggested that membrane acting AMPs, at lower 
concentrations induce transient membrane leakiness that allow the escape of ions (Huang et al., 
2006), which would disturb membrane potential and thereby ATP production. In conjunction 
with the previously mentioned observations, suggesting a metabolic standstill up until 80 
minutes, the phenomena of apparent regained membrane integrity after 80 minutes, might be 
explained by the reestablishment of membrane potential which would provide efflux pumps 
with the ATP needed for PI exclusion. In support of this, the dramatic decrease in proportion of 
bacteria with intact membranes at 10 minutes [Fig. 34] is apparently not an effect that 
translates into permanent loss of viability, by judging from the CFU counts that show a plateau 
followed by an increase, rather than a decrease [Fig. 25]. In summary, it seems conceivable to 
think that the peptides induce sufficient membrane permeabilization for the entry of PI and 
possibly disturbance of membrane potential but these processes does not translate directly into 
loss of viability. After a period of roughly 80 minutes the bacteria might reestablish membrane 
potential and thereby ATP production which could fuel efflux pumps that actively pump PI out 
of the cells. In this context it should be stressed that this mechanism is purely hypothetical and 
further studies are needed for verification. In relation to this observation, the investigation of 
Bac8c performed by Spindler and colleagues showed bacterial membrane depolarization after 5 
minutes of Bac8c exposure and recovery after 90 minutes (Spindler et al., 2011). Even if 
membrane depolarization and membrane integrity are not directly comparable they can both 
79 
 
translate into membrane disturbance to some degree and thereby extends the phenomena of 
bacterial membrane recovery after AMP exposure beyond this study.   
EFFECT ABOVE MIC EXPOSURE 
When the concentration of peptides was increased above MIC levels, the assays produced more 
consistent results, all pointing towards the same mechanism of bacterial inhibition. More  
specifically, at 2x and 4xMIC peptide exposure, both visual and quantitative assays suggest a 
rather unambiguous process of persistent membrane leakiness [Fig. 33 & 34], that by judging 
from the CFU counts [Fig. 25], also translates into loss of viability. It is a bit surprising, though 
that the proportion of live bacteria in the quantitative assay does not decrease further at 4xMIC 
exposure [Fig. 34], since CFU counts showed that the peptides could decrease the viable number 
of bacteria in the range of 1000-fold, [Fig. 25]. This could either be explained by the peptides 
exerting a lethal action that extends beyond membrane permeabilization e.g. by inhibiting 
metabolism to some degree or limitations related to the accuracy of the assay. In that context, 
substantial variation in the obtained results from the quantitative LIVE/DEAD assay, between 
individual experiments was observed [Fig. 34] and single experiments showed a decrease in the 
proportion of bacteria with intact membranes down in the range of 5% for the highest 
concentrations of peptide, which suggest assay inaccuracy to be a substantial contributor to the 
unexpected high proportion of live bacteria at 4xMIC.  
LEAKAGE FROM OF MODEL MEMBRANES 
To give additional insights into the lytic potential of the peptides, the ability to mediate release 
of calcein from POPG:POPC liposomes was investigated. Surprisingly the results revealed a 
remarkable difference in the peptides kinetic ability to mediate release.  GN-2 evidently induce 
liposome leakage instantly with no significant increase of leakage during the assay and a within 
a very narrow concentration spectrum of 5,5 to 1,7 µg/ml inducing 100- and 5% release 
respectively [Fig. 37]. The rather narrow spectrum of activity observed for GN-2, coincides with 
the proposed model of membrane active AMPs only inducing minor membrane leakage below a 
certain threshold. This is explained by the AMPs binding to the interface of the phospholipids 
parallel to the membrane (S-state) and when reaching a certain threshold changes their 
orientation into a perpendicular position (I-state), thereby inducing a more profound 
membrane disruption (Huang, 2006). Calcein release over 60 minutes, for GN-8, GN-12 and GN-
14 revealed a more distinct gradual release which progresses with increasing release up until 
about 20 minutes. A mechanism of gradual concentration dependent calcein release, followed 
by stabilization of release has previously been explained by transient pore formation (Hugonin 
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et al., 2006), followed by re-stabilization of liposomes to explain the plateau in calcein release 
(Hugonin et al., 2006; Arbuzova & Schwars, 1999), leaving partially depleted liposomes. Given 
the size of the GN-peptide of only 9 amino acids it might seem counterintuitive to assume pore 
formation, but formation of toroidal pores only requires stabilization of the pore consisting of 
both lipids and peptides rather than lining the pore as in the barrel-stave model and 
consequently does not require the peptide to span the membrane (Huang, 2006), making it a 
plausible mechanism even for 9-mers. 
 
An explanation for the immediate release exerted by GN-2 and to lesser extent of GN-4 and GN-6 
[Fig. 37], might originate from comparison with Melittin, since the kinetics of release was 
similar. Melittin has previously been shown to induce calcein release in an all-or-none manner, 
with release of all calcein content, both in POPC and POPC:POPG LUVs (Benachir & Lafleur, 
1995) which is in accordance with what is observed in this assay at the highest concentrations 
[Fig. 38]. As the release pattern over the course of one hour between GN-2 and Melittin show 
great similarity, both showing no significant increase after the initial release, it seems 
reasonable to suggest that GN-2 also exert leakage of liposomes in an all-or-none manner. In this 
context it should be stressed that Melittin induces 100 % leakage at a lipid/peptide molar ratio 
of 16,3 (3,5 µg/ml)  in comparison with a ratio of 5,4 (5,5 µg/ml) for GN-2, demonstrating their 
different potencies. In relation, Melittin has been shown to act by the mechanism of pore 
formation (Wessman et al., 2008; Allende et al., 2005) and given the similar behavior in 
mediating calcein release, it is reasonable to assign this mechanism as the best candidate to 
explain the membrane disrupting behavior of GN-2. To suggest pore formation to both gradual 
and immediate release might seem strange but apparently there is a great difference in the 
extent of pore formation.  The difference in kinetics might be related to the lifetime of pores 
(Arbuzova & Schwars, 1999; Rex & Schwarz 1998), size of pores (Rex & Schwarz 1998) and the 
number of pores (Rex & Schwarz 1998), all of which would greatly affect the release from LUVs. 
Hence, the observed difference in calcein release in this study might very well be related to 
different potencies in mediating a cumulative effect of the described determinants for liposome 
leakage by pore formation. However, other studies on Melittin has suggested that Melittin 
induces some degree of aggregation and disruption at lipid/peptide ratios below 8 (Yu et al., 
2008) and accordingly this mechanism cannot be excluded at higher concentrations for either 
Melittin or GN-2. Additionally, the precise mechanism of membrane disruption might very well 
be a mixture between different mechanism (Pistolesi et al., 2007; Teixeira et al., 2012) and the 
action of the tested peptides is therefore not likely confined to only pore formation.  
Unfortunately the timeframe of this thesis did not allow the successful creation of a mammalian 
membrane mimic with entrapped calcein, which could have given valuable insights into the 
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selective activity of the peptides. Also, it has to be kept in mind that the lipid composition of the 
LUVs is not a perfect mimic of all bacterial membranes but rather a simple model from where 
the most fundamental characteristics of negative charge is preserved, which suggest caution in 
directly transferring LUVs leakage behavior to inhibition of bacteria.   
Despite the difficulties of extrapolating data from simple models like the one used in this assay, 
the assay would suggest that membrane permeabilization is a main contributor to antibacterial 
effect exerted by these peptides. 
 
LPS INTERACTION 
The interaction of LPS which was investigated by the use of ITC indicated a binding of GN-2 and 
GN-4 to LPS, although the affinity of the binding was substantial lower than positive control of 
Polymyxin B. Because of the poor reproducibility of the assay, it does not allow any definitive 
conclusion to be made about the interaction with LPS although the negative charge of LPS and 
converse positive charge of the peptides, together with rather potent activity against gram-
negative P.aeruginosa and E.coli, suggest some degree of interaction. The nature of this putative 
interaction is, based on these studies, probably not sufficiently potent to prompt for the 
investigation of their potential as LPS neutralizing agents even though such agents are needed 
for their potential to inhibit the development of septic shock.  
SECONDARY STRUCTURE 
Secondary structure has been used for characterization but has also been tailored to both 
antibacterial and cytotoxic activity for many AMPs. In that perspective is was somewhat 
surprising to find, that although a change in the CD spectra in the presence of LUVs compared to 
Tris can be detected, there was a general lack of secondary structure among the GN-peptides. In 
the presence of bacterial mimicking liposomes the K2D algorithm was able to determine the 
ratio of secondary structure for a higher proportion of the GN-peptides in comparison with 
mammalian mimicking liposomes, most prominently predicting an α-helical content of 26 % of 
the GN-4 peptide. Interestingly, GN-4 exerted both the highest degree of hemolysis and 
cytotoxicity against Hela cells which could lead to speculation about a higher degree of α-helical 
content in this setting is not beneficial for selectivity between bacterial and mammalian cells 
within this library. When analyzing the CD spectra of the GN-peptides it has to be taken into 
consideration that the peptides are only 9-mers which limits their ability to form distinct 
secondary structure and therefore cannot be expected to form CD spectra that are comparable 
with the ones obtained by peptides of a bigger size.   
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CONCLUSION 
Potent activity against E.coli, P.aeruginosa and S.aureus was determined for the majority of the 
peptides from the GN-library, while none of the designed variants of Bac8c had improved 
antibacterial activity. A strong correlation between antibacterial activity and cytotoxicity was 
observed but meaningful therapeutic indexes were maintained for the majority of the peptides 
in the GN-library. The effect of GN-2 and GN-6 on E.coli varied according to the dose of exposure. 
At lower concentration of peptides exposure, a reversible inhibition of bacterial growth is 
induced, likely related to induction of minor membrane leakiness leading to loss of 
electrochemical gradients, from which bacteria over time recovers. The precise mechanism 
behind the putative metabolic disturbance at lower concentrations cannot be provided at this 
point and is therefore a subject for further investigations. At higher concentrations, there is 
substantial evidence of a more profound membrane disrupting effect that translates into loss of 
viability, suggesting bacterial lysis as the main mediator of antibacterial activity. The membrane 
disrupting effect was both in model systems and in E.coli shown to take effect within 10 
minutes, demonstrating a rapid antibacterial activity. No distinct secondary structure was 
identified in both mammalian and bacterial model systems suggesting an activity not related to 
specific secondary structure, though the peptide structure clearly changed in the presence of 
liposomes as compared to other aqueous buffer systems. Beyond the difference in potency and 
toxicity it was not possible to confidently differentiate the mechanism behind bacterial 
inhibition of GN-2 and GN-6. In light of the findings from the conducted assays, the main 
antibacterial effect of GN-2 and GN-6 can rather confidently be assigned to the bacterial 
membrane disruption although some degree of metabolic disturbance at lower concentrations 
cannot be excluded. In conclusion, the most active peptides of the GN-library display potent 
broad spectrum activity with therapeutic indexes that are either comparable or superior to the 
thoroughly investigated Indolicidin and Bac8c, strengthening their candidacy as excellent lead 
structures for future bacterial intervention. 
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APPENDIX I  
 
Calcein release from bacterial mimicking LUVs. 
 
 
 
 
 
 
 
  
Figure 40: Calcein release from 20 µM POPG:POPC, 7:3 molar ratio vesicles at 37°C following peptide exposure over 
the course of 1 hour. 100 % leakage was set as the release after addition of 10% Triton X-100 and all readings were 
baseline corrected by substracting values from liposomes without addition of peptides. Depicted results are the 
mean of three independent experiments with good reproducibility. Error bars are omitted for clarity 
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APPENDIX II 
 
Calculations of IC50 values from the MTT assay. 
 
 
 
 
 
 
 
 
  
 
GN-2 GN-3 GN-4 GN-5 GN-6 
log(inhibitor) vs. normalized response 
-- Variable slope 
     
Best-fit values 
          
LOGIC50 
1,670 2,026 1,568 2,119 1,988 
HILLSLOPE 
-3,251 -2,406 -2,321 -3,428 -4,030 
IC50 
46,76 106,1 36,95 131,4 97,23 
Std. Error 
          
LOGIC50 
0,02705 0,04670 0,03632 0,02736 0,02089 
HILLSLOPE 
0,6059 0,6042 0,4612 0,6203 0,9673 
95% Confidence Intervals 
          
LOGIC50 
1.613 to 1.726 1.928 to 2.123 1.492 to 1.644 2.061 to 2.176 1.944 to 2.031 
HILLSLOPE 
-4.515 to -1.988 -3.662 to -1.149 -3.286 to -1.355 -4.722 to -2.134 -6.042 to -2.019 
IC50 
41.07 to 53.25 84.80 to 132.6 31.01 to 44.01 115.2 to 149.8 87.97 to 107.5 
Goodness of Fit 
          
Degrees of Freedom 
20 21 19 20 21 
R² 
0,8893 0,7298 0,7740 0,8586 0,9028 
Absolute Sum of Squares 
3269 7936 4113 3361 3197 
Sy.x 
12,78 19,44 14,71 12,96 12,34 
Number of points 
          
Analyzed 
22 23 21 22 23 
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Calculations of IC50 values from the MTT assay. 
 
 
GN-8 GN-9 GN-11 GN-12 GN-14 
 
     
log(inhibitor) vs. normalized 
response -- Variable slope 
  Ambiguous   Ambiguous Not converged 
Best-fit values 
         
LOGIC50 
2,298 ~ 2.332 2,625 ~ 2.239   
HILLSLOPE 
-3,117 ~ -22.56 -3,134 ~ -21.26   
IC50 
198,7 ~ 214.8 421,8 ~ 173.2   
Std. Error 
          
LOGIC50 
0,03470 ~ 3183 0,8214 ~ 19.64   
HILLSLOPE 
0,8341 ~ 2.312e+006 7,717 ~ 6680   
95% Confidence Intervals 
2.226 to 2.371 (Very wide) 
 
0.9165 to 4.334 (Very wide)   
LOGIC50 
-4.857 to -1.378 (Very wide) -19.19 to 12.92 (Very wide)  
HILLSLOPE 
168.2 to 234.8 (Very wide) 8.252 to 21566 (Very wide)   
IC50 
      
Goodness of Fit 
          
Degrees of Freedom 
20 21 21 21   
R² 
0,7222 0,2766 0,06424 0,9486   
Absolute Sum of Squares 
3170 3332 4300 1942   
Sy.x 
12,59 12,60 14,31 9,617   
Number of points 
          
Analyzed 
22 23 23 23 20 
 
